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ABSTRACT
Properties of a Dehydroalanine Analog of Glutathione: A Reactive Electrophilic Busulfan
Metabolite
Cody J. Peer
Gamma-Glutamyldehydroalanylglycine (EdAG) is a dethiolated, electrophilic metabolite of
glutathione (GSH) derived from the Phase II conjugation of GSH with busulfan catalyzed by
glutathione S-transferase (GST). It was demonstrated in this dissertation that EdAG could be
successfully synthesized and shown to be a metabolite of busulfan from in vitro metabolism by
enzymes in human liver cytosol. The electrophilic EdAG was reactive toward the cellular thiols
cysteine and glutathione (GSH), and toward cysteine residues in reduced bovine insulin B-chain
and bovine serum albumin in vitro, as well. EdAG was demonstrated to be a reversible
noncompetitive inhibitor of GSTs, specifically GSTA1-1 at micromolar concentrations up to 1
mM. EdAG at high concentration (10 mM) was found to be an irreversible inhibitor of human
GSTA1-1, although an EdAG-modified peptide was not observed. Inhibition of GST by a
busulfan metabolite has the potential of altering busulfan pharmacokinetics or GSH cellular
function. Since conversion of GSH to EdAG represents a loss of thiol-related redox properties
and the gain of a captodative radical scavenging dehydroalanine group, the reactivity of EdAG
with hydroxyl radical was evaluated. EdAG was shown to scavenge hydroxyl radical generated
in the Fenton reaction in a concentration-dependent manner. The results indicate a stabilized
carbon-based captodative radical intermediate in the reaction of EdAG with hydroxyl radical. In
support of a captodative mechanism was the identification of a dimerized γ-glutamylserylglycine
as a product in the reaction. Conversion of GSH from a redox active nucleophile to an
electrophilic dehydroalanine is a significant change in chemical reactivity that may have
biological implications for GSH and free radical biochemistry as well as busulfan therapeutics.
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Chapter 1
Introduction
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1.1

Drug Metabolism
Nearly all complex organisms have built-in mechanisms for eliminating foreign

compounds, or xenobiotics. Typically, the objective is to make those xenobiotics more water
soluble in order to be eliminated. Involved in these processes are a variety of enzymes,
substrates, and co-factors. The structure and properties of the xenobiotic determines the
metabolic pathway that will metabolize the compound, however any single xenobiotic isn’t
necessarily limited to one specific pathway. There are two major routes, or phases, of
metabolism that is dependent on the xenobiotic involved. Each phase employs certain enzymes,
cofactors, and substrates to make the xenobiotic more polar and thus eliminated.
Phase I metabolism usually occurs in the liver or gut lumen, where xenobiotics are
subjected to oxidation, reduction, or hydrolysis by enzymes such as the cytochrome P450
(CYP450) superfamily of enzymes and flavin monooxygenases (FMOs). There are a variety of
metabolic mechanisms used to make the xenobiotic more polar and prepare it for elimination or
further metabolism. The phase I-mediated mechanisms include, but are not limited to, side chain
oxidation, aromatic ring oxidation, methyl oxidation, heterocyclic ring oxidation, N-dealkylation,
O-dealkylation, S-dealkylation, deamination, N-oxidation, sulfoxidation, and azoreduction.
Phase II metabolism has the same basic function as phase I, that being to make the
xenobiotic more polar to eliminate it from the organism. Phase II metabolism can occur on
either a previously unmetabolized xenobiotic or one that underwent phase I metabolism. Phase
II metabolic processes include, but are not limited to, glucuronidation, sulfation, acetylation, and
conjugation with the abundant endogenous cellular nucleophilic tripeptide, glutathione (GSH).
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1.1.1

Phase II Conjugation with Glutathione
Phase II conjugation of xenobiotics with GSH is the result of catalysis by the glutathione

S-transferase (GST) superfamily of enzymes. The addition of glutathione to endogenous or
xenobiotic hydrophobic electrophiles render those adducts more water-soluble and thus, more
readily eliminated from the body. Glutathione adducts are also subject to cellular efflux and
further metabolism by the Mercapturic acid pathway, leading to polar cysteine-S-conjugates.
There are many different sub-families of the GSTs based on their subcellular localization as
either membrane-bound, mitochondrial, or cytosolic. Nomenclature of the different classes of
GSTs is based on Greek letters (e.g. alpha, pi, mu), but abbreviated with Roman capital letters
(e.g. A, P, M) (1). The membrane-bound classes of GSTs include three isoforms: microsomal I,
microsomal II, and leukotriene C4 (LTC4), that are structurally very different from their cytosolic
counterparts (2). Not much is known about these three classes of GSH transferases, however
they are nonetheless important in detoxification of certain electrophilic compounds. The
cytosolic classes of GSTs have been studied much more extensively and thus more structural and
mechanistic information is known. The classes of the soluble (cytosolic) GST isoforms that are
known include, but may not be limited to if new classes have since been discovered, alpha, zeta,
theta, mu, pi, sigma, and omega (3).
The genetic origin has been extensively studied to determine the similarities between the
classes of the GST superfamily of enzymes. GST isoforms of the same class (e.g. alpha) are
classified together because their genes are located in very close proximity to each other on the
same chromosome (3). GSTs are also dimeric proteins, but can only dimerize with isoforms
within the same class. For example, the human GST alpha class (hGSTA) contains two major
isoforms, hGSTA1 and hGSTA2. Between these two isoforms, three different dimeric proteins
3

can form; the homodimeric hGSTA1-1 and hGSTA2-2, or the heterodimeric hGSTA1-2. The
genes for each isoform is written italicized, e.g. hGSTA1.
Most of the seven soluble classes of GSTs have been crystallized and their quaternary
and secondary subunit structures revealed. Cytosolic GSTs are all slightly different in terms of
their primary amino acid sequence and tissue abundance, but all have similar protein folding and
overall quaternary structure. The C-terminal domain accounts for two thirds of the protein
structure and consists mostly of alpha helices (2). One of the major structural differences among
the soluble GST classes is the substrate specificity for the electrophilic substrate to be conjugated
by GSH. The hydrophobic substrate binding site, or H-site, is structurally unique for each
isoenzyme within each class. The H-site is located within the crevice that forms between the Nterminal domain I and the C-terminal domain II. The N-terminal domain consists of mixtures of
α-helices and β-sheets and account for the remaining one third of the overall protein structure.
Cytosolic GSTs all serve the same purpose of conjugating GSH to electrophilic substrates, thus
all soluble GST classes need to bind GSH. Domain I contains similar secondary structural
features across cytosolic GST classes because this accounts for the GSH binding site, or G-site.
There are some differences in domain I between the classes in terms of the GSH recognition
residues among classes and species, namely different residues responsible for docking and
activating the GSH in the G-site. Most GST classes utilize a tyrosine residue positioned near the
docked GSH to form hydrogen bonds to the thiol to deprotonate and stabilize the thiolate. Only
theta class GSTs utilize a serine residue to hydrogen bond GSH (4). In human GSTA1-1, Arg15
and Tyr9 both form hydrogen bonds to the thiol of GSH when docked in the G-site (5). This
helps lower the pKa of GST-bound GSH from 9 to about 6.6 (6).
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1.2

Glutathione
Glutathione (GSH) is an abundant cellular tripeptide consisting of L-glutamic acid, L-

cysteine, and glycine. It is present in millimolar concentrations intracellularly and in micromolar
concentrations in plasma and urine. It is the major source of cysteine and thiols in animals and
plants. It is synthesized intracellularly, first by the rate-limiting addition of L-glutamate and Lcysteine by the ATP-dependent γ-glutamylcysteine synthetase (7,8), followed by addition of
glycine to the C-terminal end of γ-glutamylcysteine by the ATP-dependent glutathione
synthetase (9). The cysteine residue contains a reactive and nucleophilic thiol side chain (-SH).
The major roles of glutathione, as they pertain to this dissertation research, are two-fold: as a
cellular nucleophile to conjugate and detoxify electrophilic compounds (in reactions catalyzed by
GSTs), and as a cellular redox agent that scavenges reactive oxygen species (ROS) (10). Other
roles of GSH include autoimmunity and transhydrogenation with compounds such as ascorbic
acid (11). Glutathionylation of proteins occurs during states of oxidative stress and is
categorized as a redox mechanism involving GSH. Often times, glutathionylated hemoglobin is
a biomarker for oxidative stress (12).
Glutathione plays a major role in maintaining redox equilibrium in a cell. During normal
physiological conditions for yeast cytoplasm, there are low steady state levels of ROS, thus
oxidative stress is low (13). Most glutathione exists in the reduced form (GSH at pH 7.4, pKa 9),
the levels of which are about 3000-fold more than the oxidized glutathione (GSSG) levels due to
efficient reduction mechanisms (14). Normal cellular functions of mitochondria, peroxisomes,
and other physiological cellular oxidative process require the need for redox mechanisms for
their constant removal. There are many glutathione-dependent enzymes and mechanisms
responsible for reduction of cytosolic ROS species, including GSH-dependent thiol peroxidases,
5

thioredoxin, and glutaredoxin (15). Thioredoxin and glutaredoxin are primarily responsible for
maintaining protein thiol oxidation in the cytosol. Another enzyme, glutathione reductase (GR),
plays a major role in cellular redox state by reducing the oxidized GSSG back to GSH for
recycling and continued redox scavenging. GR is a homodimeric enzyme containing FAD that
requires NADPH for electron donation and is a very efficient reaction, with GSSG having a
relatively low binding affinity (KM = 55 µM) considering the millimolar glutathione
concentrations found intracellularly (16).
Phase II conjugation of xenobiotics with GSH is catalyzed by the GST superfamily of
enzymes. Among those xenobiotics that undergo this metabolism are numerous anticancer
agents, specifically DNA alkylating agents, because they are electrophilic. Compounds must be
electrophilic in order to be conjugated by nucleophilic atoms on DNA nucleotides (e.g. N7 of
guanine bases). There are five classifications of DNA alkylating groups based on their structure
and anticancer mechanism: nitrogen mustards, nitrosoureas, ethylenimines, triazenes, and alkyl
sulfonates (17). Of interest to this dissertation research was the alkyl sulfonate anticancer agent
busulfan, due to its phase II GSH conjugation and resulting metabolite that is a dethiolated
glutathione.

1.3

Busulfan
Busulfan is a bifunctional anticancer agent that is classified as an alkyl sulfonate as part

of the larger group of anticancer drugs known as DNA-alkylating agents. Busulfan contains
sulfonate groups on both ends of the molecule (Figure 1.3.1) that allow it to be reactive towards
DNA on both ends. The carbons adjacent to the electron-withdrawing sulfonate groups are
electrophilic and are susceptible to nucleophilic attack.
6

Figure 1.3.1 Busulfan

This allows either end of busulfan to be conjugated by nucleophilic atoms on DNA nucleotides,
such as the N7 atom on guanine bases. Busulfan was developed in the 1950s and first used
clinically as a chemotherapeutic in 1959. Initially, busulfan was used to treat chronic
myelogenous leukemia (18,19) but is also now used in high doses along with cyclophosphamide
for myeloablative conditioning therapy prior to bone marrow transplants and hematopoietic stem
cell transplants (20), as well as polycythemia rubra vera (21) and essential thrombocythemia
(22).
Busulfan is metabolized by phase II conjugation with GSH catalyzed by the GST
superfamily of enzymes, but predominantly cytosolic GSTA1-1 in liver hepatocytes (23). The
hydrophobic busulfan, which is typically administered orally or through intravenous emulsion
solutions, is a good substrate for the hydrophobic binding site (H-site) on GSTA1-1. The
product formed by GSTs, which is released back to the intrahepatocellular cytosol, is an unstable
sulfonium ion (γ-glutamyl-β-[S-tetrahydrothiophenium]alanylglycine; GS+THT) (24). It was
shown by Younis et al that GS+THT slowly degrades at pH 7.4 by a base-catalyzed βelimination reaction of tetrahydrothiophene (THT), and the degradation occurs faster at pH 8.4
(25). The portion of GS+THT remaining after elimination of THT is a dethiolated analog of
GSH, γ-glutamyldehydroalanylglycine (EdAG) as depicted in Scheme 1.1.
7

Scheme 1.1

Busulfan Metabolism Catalyzed by GSTA1-1

EdAG contains a dehydroalanyl residue in lieu of the cysteinyl residue in GSH that potentially
alters the chemical properties of the molecule. The moiety of glutathione that enabled the
molecule to have such important and wide-ranging functions, the nucleophilic thiol side chain on
the cysteinyl residue, is now replaced with an electrophilic vinylic carbon. Dehydroalanines are
not a novel species, however much has already been studied including formation and occurrences
in vivo.

1.4

Dehydroalanines

1.4.1

Formation of Dehydroalanines
Dehydroalanines are amino acid residues found within proteins or peptides. They can be

formed either naturally by cellular processes (e.g. post-translational modifications) or chemically
(e.g. food processing). Dehydroalanines (Dha) and dehydrobutyrines (Dhb) are mainly formed
8

from serine and threonine residues, respectively, by the same mechanism under conditions of
high pH and temperature (26). Dha residues formed from cysteine residues in vivo are rare aside
from chemically-induced non-physiological reactions (27).
One such setting that provides these conditions is during food processing, where many
proteins in meat and other processed foods contain cysteine residues that undergo a basecatalyzed β-elimination induced by heat and/or the alkaline environment (28). Another more
naturally-occurring scenario where the dehydration of serine and threonine can occur is during
an in situ alkaline environment, where basic amino acids near a serine or threonine could induce
a β-elimination forming Dha and Dhb, respectively (29). Posttranslationally-modified peptides
made by ribosomes within Gram-positive bacteria contain many Dha or Dhb residues that can be
further modified by nucleophilic addition by a cysteine residue to form a nonreducible
lanthionine thioether (Ala-S-Ala). Proteins that contain these lanthionines produced by
ribosomes in Gram-positive bacteria have antibiotic properties and are referred to as lantibiotics
(30).

1.4.2 Lantibiotics are peptides that contain dehydroalanine crosslinks with cysteines
The 1928 discovery of a substance produced by a colony of bacteria that inhibited its
further growth was the birth of lantibiotics (31). Gram positive bacteria produce a variety of
peptides called bacteriocins, of which those that contain lanthionine or β-methyl lanthionine
crosslinks are called lantibiotics. When lantibiotics are ribosomally synthesized and
posttranslationally modified, numerous serines and threonines are transformed into
dehydroalanine or dehydrobutyrine residues, respectively. These serine/threonine residues are
phosphorylated by serine/threonine kinases followed by dehydration by dehydratases and
9

cyclization with nearby cysteine residues (forming the lanthionine) by cyclases before
proteolysis of the leader peptide (32). Serines and threonines within the leader portion of the
peptide are not subject to modification to Dha and Dhb, respectively, however within the
propeptide portion, serines are twice as likely to avoid modifications as threonines (33). The
incidence of modification and cyclization are dependent upon the amino acids flanking the
modified dehydrated amino acids. It was determined that hydrophobic, nonaromatic amino acids
more often flank serines and threonines that become modified (33). Dha and Dhb can then react
with cysteine residues flanked by less hydrophobic amino acid residues near the C-terminus
within the same peptide to form the lanthionine or β-methyl lanthionine crosslinks, respectively,
that are integral in the efficacy of the lantibiotic as an antimicrobial agent. The thioether
crosslinks that form the bridges are very important to the structural stability and antimicrobial
efficacy of the lantibiotic (34,35). The structural rigidity of lantibiotics is dependent upon the
thioether rings, as well as the peptide’s resistance to proteolysis and heat, which are also ringdependent (36). The LanB dehydratases are nonspecific concerning stereochemistry, but the
LanC cyclases, in addition to the stereospecificity of the peptide sequence, play a role in
determining ring formation (37-39). Due to their stability and resistance to proteolysis,
lantibiotics have not shown as much bacterial resistance as conventional antibiotics have.
Lantibiotics could serve as a novel antibiotic for drug-resistant strands of bacteria.
Lantiobiotics are classified into two types, depending on their shape and functionality.
Type A lantibiotics are typically amphiphilic and elongated peptides and target the cell
membrane of bacteria to form pores that induces bacterial death (40). Type B are globular
proteins that bind to lipids in bacterial cell membranes that effectively halt production of
membrane lipids by inhibiting the enzymes that produce them. Lantibiotics are cationic peptides
10

that are effective in much lower concentrations than those cationic peptides typically
manufactured by mammals, insects, fish, and amphibians (41). Type A lantibiotics use LanB
dehydratases and LanC cyclases to transform serine/threonine residues to Dha/Dhb, respectively,
and type B lantibiotics use LanM proteins that execute the same reactions in type B lantibiotics
as LanB and LanC enzymes for type A lantibiotics (42,43). Based on the modes of action, which
is determined by the type of lantibiotic (A or B), there are many lantibiotics that have potential in
treating bacterial diseases like acne and MRSA (Nisin A, Lacticin 3147, Gallidermin, Epidermin,
Mutacin 1140, Mersacidin, Actagardine) as well as inflammation (Duramycin) and regulation of
blood pressure (Cinnamycin, Ancovenin) (44).
Nisin, the common food preservative, is the most known and studied lantibiotic. Due to
its antibiotic properties and structure that enable it to avoid proteolysis and thermal degradation,
it is widely used to preserve such foods as vegetables, canned goods, dairy products, and natural
cheeses (45). Nisin contains many dehydroalanines that are not within thioether rings, thus they
are susceptible to conjugation by nucleophiles outside of the peptide (e.g. glutathione). It is not
as potent in preserving meat because it is suspected that the high GSH content in meat tissue can
form other thioethers with dehydro amino acids in the peptide (46). Synthetic dehydroalanines
occur in proteins of food during food processing due to the high temperature and alkali
conditions.

1.5

Research Objectives
Busulfan is known to be metabolized via GSTA1-1 catalyzed phase II glutathione

conjugation to form the unstable sulfonium GS+THT. The degradation product of the enzyme
metabolized product, GS+THT, is the dehydroalanine analog of glutathione, EdAG (Scheme 1.1).
11

EdAG has been previously shown to bind GSTs (25). The electrophilic nature of the
dehydroalanine renders EdAG reactive towards cellular nucleophiles. Also, it was suggested that
like other dehydroalanine-containing compounds, EdAG could also react with radicals, such as
hydroxyl radical. Thus, it was the focus of the research presented here to determine the
following:
1. Identify EdAG as an in vitro product of busulfan metabolism with GSTs based on
LC/MS characteristics compared to a synthesized EdAG standard.
2. Determine the reactivity of EdAG toward the cellular nucleophiles GSH and Lcysteine, as well as cysteine residues in proteins using insulin and bovine serum albumin
as model proteins.
3. Determine if EdAG is inhibiting GSTs and elucidate the mechanism of EdAG-induced
inhibition of GSTs over a wide concentration range.
4. Characterize the radical scavenging activity of EdAG towards the ROS hydroxyl
radical using electron paramagnetic resonance (EPR) spectroscopy and mass
spectrometry.

12

REFERENCES

(1) Mannervik, B., Awasthi, Y. C., Board, P. G., Hayes, J. D., Di, I. C., Ketterer, B.,
Listowsky, I., Morgenstern, R., Muramatsu, M., Pearson, W. R., and . (1992)
Nomenclature for human glutathione transferases. Biochem. J. 282 ( Pt 1), 305306.
(2) Armstrong, R. N. (1997) Structure, catalytic mechanism, and evolution of the
glutathione transferases. Chem. Res. Toxicol. 10(1), 2-18.
(3) Mannervik, B., Board, P. G., Hayes, J. D., Listowsky, I., and Pearson, W. R. (2005)
Nomenclature for mammalian soluble glutathione transferases. Methods Enzymol.
401, 1-8.
(4) Board, P. G., Coggan, M., Wilce, M. C., and Parker, M. W. (1995) Evidence for an
essential serine residue in the active site of the Theta class glutathione
transferases. Biochem. J. 311 ( Pt 1), 247-250.
(5) Bjornestedt, R., Stenberg, G., Widersten, M., Board, P. G., Sinning, I., Jones, T. A., and
Mannervik, B. (1995) Functional significance of arginine 15 in the active site of
human class alpha glutathione transferase A1-1. J. Mol. Biol. 247(4), 765-773.
(6) Graminski, G. F., Kubo, Y., and Armstrong, R. N. (1989) Spectroscopic and kinetic
evidence for the thiolate anion of glutathione at the active site of glutathione Stransferase. Biochemistry 28(8), 3562-3568.

13

(7) Griffith, O. W., and Mulcahy, R. T. (1999) The enzymes of glutathione synthesis:
gamma-glutamylcysteine synthetase. Adv. Enzymol. Relat Areas Mol. Biol. 73,
209-67, xii.
(8) Snoke, J. E., Yanari, S., and Bloch, K. (1953) Synthesis of glutathione from gammaglutamylcysteine. J. Biol. Chem. 201(2), 573-586.
(9) Snoke, J. E., and Bloch, K. (1955) Studies on the mechanism of action of glutathione
synthetase. J. Biol. Chem. 213(2), 825-835.
(10) Hayes, J. D., and McLellan, L. I. (1999) Glutathione and glutathione-dependent enzymes
represent a co-ordinately regulated defence against oxidative stress. Free Radic.
Res. 31(4), 273-300.
(11) Perricone, C., De, C. C., and Perricone, R. (2009) Glutathione: a key player in
autoimmunity. Autoimmun. Rev. 8(8), 697-701.
(12) Bursell, S. E., and King, G. L. (2000) The potential use of glutathionyl hemoglobin as a
clinical marker of oxidative stress. Clin. Chem. 46(2), 145-146.
(13) Heeren, G., Jarolim, S., Laun, P., Rinnerthaler, M., Stolze, K., Perrone, G. G., Kohlwein,
S. D., Nohl, H., Dawes, I. W., and Breitenbach, M. (2004) The role of
respiration, reactive oxygen species and oxidative stress in mother cell-specific
ageing of yeast strains defective in the RAS signalling pathway. FEMS Yeast Res.
5(2), 157-167.
(14) Ostergaard, H., Tachibana, C., and Winther, J. R. (2004) Monitoring disulfide bond
formation in the eukaryotic cytosol. J. Cell Biol. 166(3), 337-345.
(15) Lopez-Mirabal, H. R., and Winther, J. R. (2008) Redox characteristics of the eukaryotic
cytosol. Biochim. Biophys. Acta 1783(4), 629-640.
14

(16) Massey, V., and Williams, C. H., Jr. (1965) On the reaction mechanism of yeast
glutathione reductase. J. Biol. Chem. 240(11), 4470-4480.
(17) Dirven, H. A., van, O. B., and van Bladeren, P. J. (1996) Glutathione conjugation of
alkylating cytostatic drugs with a nitrogen mustard group and the role of
glutathione S-transferases. Chem. Res. Toxicol. 9(2), 351-360.
(18) Silver, R. T. (2003) Chronic myeloid leukemia. Hematol. Oncol. Clin. North Am. 17(5),
1159-1vii.
(19) Stone, R. M. (2004) Optimizing treatment of chronic myeloid leukemia: a rational
approach. Oncologist. 9(3), 259-270.
(20) Russell, S., and Vowels, M. (1992) Busulphan, cyclophosphamide, and melphalan as
conditioning therapy in allogeneic bone marrow transplants for acute
lymphoblastic leukemia. Transplant. Proc. 24(1), 183.
(21) Mital, A., Czyz, J., and Hellmann, A. (1996) [Evaluation of treatment results in patients
with polycythemia rubra vera]. Pol. Arch. Med. Wewn. 95(5), 453-458.
(22) Van de Pette, J. E., Prochazka, A. V., Pearson, T. C., Singh, A. K., Dickson, E. R., and
Wetherley-Mein, G. (1986) Primary thrombocythaemia treated with busulphan.
Br. J. Haematol. 62(2), 229-237.
(23) Czerwinski, M., Gibbs, J. P., and Slattery, J. T. (1996) Busulfan conjugation by
glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 24(9), 10151019.
(24) Roberts, J. J., and Warwick, G. P. (1961) The mode of action of alkylating agents. II.
Studies of the metabolism of myleran. The reaction of myleran with some
naturally occurring thiols in vitro. Biochem. Pharmacol. 6, 205-216.
15

(25) Younis, I. R., Elliott, M., Peer, C. J., Cooper, A. J., Pinto, J. T., Konat, G. W.,
Kraszpulski, M., Petros, W. P., and Callery, P. S. (2008) Dehydroalanine analog
of glutathione: an electrophilic busulfan metabolite that binds to human
glutathione S-transferase A1-1. J. Pharmacol. Exp. Ther. 327(3), 770-776.
(26) Finley, J. W., and Friedman, M. (1977) New amino acid derivatives formed by alkaline
treatment of proteins. Adv. Exp. Med. Biol. 86B, 123-130.
(27) Bernardes, G. J., Chalker, J. M., Errey, J. C., and Davis, B. G. (2008) Facile conversion
of cysteine and alkyl cysteines to dehydroalanine on protein surfaces: versatile
and switchable access to functionalized proteins. J. Am. Chem. Soc. 130(15),
5052-5053.
(28) Friedman, M. (1999) Chemistry, biochemistry, nutrition, and microbiology of
lysinoalanine, lanthionine, and histidinoalanine in food and other proteins. J.
Agric. Food Chem. 47(4), 1295-1319.
(29) Nakanishi, T., Sato, T., Sakoda, S., Yoshioka, M., and Shimizu, A. (2004) Modification
of cysteine residue in transthyretin and a synthetic peptide: analyses by
electrospray ionization mass spectrometry. Biochim. Biophys. Acta 1698(1), 4553.
(30) Chatterjee, C., Paul, M., Xie, L., and van der Donk, W. A. (2005) Biosynthesis and mode
of action of lantibiotics. Chem. Rev. 105(2), 633-684.
(31) Rogers, L. A., and Whittier, E. O. (1928) Limiting Factors in the Lactic Fermentattion.
J. Bacteriol. 16(4), 211-229.

16

(32) Okeley, N. M., Paul, M., Stasser, J. P., Blackburn, N., and van der Donk, W. A. (2003)
SpaC and NisC, the cyclases involved in subtilin and nisin biosynthesis, are zinc
proteins. Biochemistry 42(46), 13613-13624.
(33) Rink, R., Kuipers, A., de, B. E., Leenhouts, K. J., Driessen, A. J., Moll, G. N., and
Kuipers, O. P. (2005) Lantibiotic structures as guidelines for the design of
peptides that can be modified by lantibiotic enzymes. Biochemistry 44(24), 88738882.
(34) Bierbaum, G., Szekat, C., Josten, M., Heidrich, C., Kempter, C., Jung, G., and Sahl, H. G.
(1996) Engineering of a novel thioether bridge and role of modified residues in
the lantibiotic Pep5. Appl. Environ. Microbiol. 62(2), 385-392.
(35) van, K. C., Breukink, E., Rollema, H. S., Bongers, R. S., Kosters, H. A., de, K. B., and
Kuipers, O. P. (2000) Engineering a disulfide bond and free thiols in the
lantibiotic nisin Z. Eur. J. Biochem. 267(3), 901-909.
(36) Kuipers, O. P., Bierbaum, G., Ottenwalder, B., Dodd, H. M., Horn, N., Metzger, J.,
Kupke, T., Gnau, V., Bongers, R., van den, B. P., Kosters, H., Rollema, H. S., de
Vos, W. M., Siezen, R. J., Jung, G., Gotz, F., Sahl, H. G., and Gasson, M. J.
(1996) Protein engineering of lantibiotics. Antonie Van Leeuwenhoek 69(2), 161169.
(37) Burrage, S., Raynham, T., Williams, G., Essex, J. W., Allen, C., Cardno, M., Swali, V.,
and Bradley, M. (2000) Biomimetic synthesis of lantibiotics. Chemistry. 6(8),
1455-1466.
(38) Zhou, H., and van der Donk, W. A. (2002) Biomimetic stereoselective formation of
methyllanthionine. Org. Lett. 4(8), 1335-1338.
17

(39) Zhu, Y., Gieselman, M. D., Zhou, H., Averin, O., and van der Donk, W. A. (2003)
Biomimetic studies on the mechanism of stereoselective lanthionine formation.
Org. Biomol. Chem. 1(19), 3304-3315.
(40) Jung, G., and Sahl, H. G. (1991) Nisin and Novel Lantibiotics. (Jung, G., and Sahl, H.
G., Eds.) pp 1-34, Escom,
(41) Breukink, E., Wiedemann, I., van, K. C., Kuipers, O. P., Sahl, H., and de, K. B. (1999)
Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic.
Science 286(5448), 2361-2364.
(42) Sahl, H. G., and Bierbaum, G. (1998) Lantibiotics: biosynthesis and biological activities
of uniquely modified peptides from gram-positive bacteria. Annu. Rev. Microbiol.
52, 41-79.
(43) Siezen, R. J., Kuipers, O. P., and de Vos, W. M. (1996) Comparison of lantibiotic gene
clusters and encoded proteins. Antonie Van Leeuwenhoek 69(2), 171-184.
(44) Ryan, M. P., Hill, C., and Ross, R. P. (2002) Peptide antibiotics - discovery, modes of
action and applications. (Dutton, C. J., Haxell, M. A., McArthur, M. A. I., and
Wax, R. G., Eds.) pp 193-242, Marcel Dekker,
(45) ves-Broughton, J., Blackburn, P., Evans, R. J., and Hugenholtz, J. (1996) Applications of
the bacteriocin, nisin. Antonie Van Leeuwenhoek 69(2), 193-202.
(46) Rose, N. L., Sporns, P., Dodd, H. M., Gasson, M. J., Mellon, F. A., and McMullen, L. M.
(2003) Involvement of dehydroalanine and dehydrobutyrine in the addition of
glutathione to nisin. J. Agric. Food Chem. 51(10), 3174-3178.

18

Chapter 2

Identification of EdAG as a metabolite from in
vitro Busulfan-GSH conjugation catalyzed by
GSTs
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INTRODUCTION

2.1.1

Busulfan
Busulfan, or 1,4-butanediol dimethanesulfonate, is a bifunctional DNA alkylating agent

classified as an alkyl sulfonate. Busulfan, like other alkylating agents, induces its effects by
donating an alkyl group to nucleophilic biomolecules, such as DNA. The mechanism of action
of busulfan is to bind DNA in rapidly-dividing cells (e.g. cancer cells) to prevent replication.
The primary site of action on DNA is the N7 atom on guanine nucleotides, although other atoms
provide secondary sites of action. Busulfan forms intrastrand cross-links at the 5’-GA-3’
sequence, as well as monoalkylation on the N7 of guanine, in a dose-dependent manner (1).
Busulfan was introduced in 1959 as a chemotherapeutic agent to treat myeloproliferative
disorders. Initially, busulfan was used to treat chronic myelogenous leukemia (2,3) but is also
now used in high doses along with cyclophosphamide for myeloablative conditioning therapy for
bone marrow transplants and hematopoietic stem cell transplants (4), as well as polycythemia
rubra vera (5) and essential thrombocythemia (6).

2.1.2 Busulfan Absorption, Distribution, Metabolism, and Elimination (ADME)
Busulfan pharmacokinetics have been extensively studied as the oral formulation, and
only more recently studied as the intravenous (i.v.) formulation. Busulfan disposition following
oral dosing can best be described by a one-compartment open model. Oral formulations were
originally marketed as Myleran® by GlaxoSmithKline with relatively good bioavailability (mean
80%), but varied greatly. Recently, the organic solvent N,N-dimethylacetamide (DMA) has been
used to solvate the highly lipophilic busulfan into aqueous solution for i.v. administration. The
20

market name for the i.v. formulation is Busulfex® (Otsuka), and is composed of 6 mg/kg
busulfan solvated in 33% DMA (v/v) and 67% polyethylene glycol 400 (v/v). Each Busulfex®
vial is then diluted further to a busulfan concentration of 0.5 mg/mL in 0.9% saline or 5%
dextrose with a pH range of 3.4-3.9. Comparisons of bioavailability and exposure between oral
and i.v. formulations have shown that a 1 mg/kg oral dose is bioequivalent to a 0.8 mg/kg i.v.
dose of busulfan (7). There has been a recent switch in busulfan formulation usage from oral to
i.v. because the intravenous route is easier to perform therapeutic drug monitoring to ensure
busulfan exposure remains below the target level of 1,500 µMymin to avoid toxicity such as
hepatic veno-occlusive disease (HVOD) (8).
Oral busulfan has very high interpatient pharmacokinetic variability that is affected by
various conditions such as circadian rhythmicity, disease states, age, and dosage (9-12), with
either a zero-order absorption (13) or first-order absorption (14,15). Time to maximum
absorption (tmax) range between 0.5-1 hour, however some patients can absorb busulfan
immediately whereas others (up to 25%) have lag times of up to an hour (16). Busulfan
disposition is best described by a one-compartment open model. Roughly 1% of busulfan is
excreted in urine as unchanged (13). Typical elimination half-lives did not vary significantly
between children and adults, with average half-lives in children of 2.5 hours (17-19), and in
adults of 2.75 hours (20).
Orally-administered busulfan is absorbed from the gastrointestinal (GI) tract into the
hepatic portal circulation, where it undergoes first-pass metabolism from either the gut or liver,
or both, prior to distribution into the systemic circulation. GSTA1-1, the major enzyme
responsible for busulfan metabolism, is mainly located in the liver but is also found in the
intestinal wall epithelia. The first-pass effect can ultimately lower the bioavailability of an oral
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drug, thus decreasing its exposure and altering its pharmacokinetics. In the systemic circulation,
busulfan has a relatively low binding affinity to plasma proteins, where 32.4% of busulfan dose
is irreversibly bound (21). Intravenous busulfan avoids first-pass metabolism and thus exposure
and clearance are not affected by this effect. Busulfan is also evenly distributed between plasma
and blood cells, where 46.9% of the busulfan dose was irreversibly bound to blood cells to
induce a myeloablative effect (21). A significant portion (20%) of busulfan is able to cross the
blood brain barrier (22). Busulfan concentrations in the cerebrospinal fluid were significant
enough to be monitored and elimination parameters calculated (23-25).
The major route of busulfan metabolism is glutathione S-transferase (GST)-catalyzed
GSH conjugation, which forms a relatively unstable sulfonium ion (γ-glutamyl-β-[Stetrahydrothiophenium]alanylglycine; GS+THT) (26). The major GST isoform responsible for
busulfan conjugation to GSH is the cytosolic GSTA1-1 (27). The sulfonium is further
metabolized by either of two pathways. The first pathway is the Mercapturic acid pathway
(MCA), where the sulfonium is cleaved by a variety of enzymes that produce the final product of
a N-acetylcysteine-S-sulfonium conjugate (28). The purpose of the MCA pathway is to detoxify
toxic compounds, however the product of the second to last step of the MCA pathway is a
cysteine S-conjugate. This compound can either be N-acetylated with Acetyl CoA by Nacetyltransferase, or can be a substrate for a class of enzymes called cysteine-S-conjugate βlyases. These enzymes cleave the thioether linkage, forming a dehydrocystine (later rearranges
to α-imino acid before hydrolyzing to pyruvate and ammonium) and a sulfur-containing moiety,
that is potentially toxic when reabsorbed from the gut lumen or renal proximal tubule
recirculation. The second pathway that the GS+THT sulfonium can follow is through a
nonenzymatic β-elimination of tetrahydrothiophene (THT) (26), which produces an electrophilic
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dehydroalanine analog of glutathione, γ-glutamyldehydroalanylglycine (EdAG) (29) (Scheme
1.1).
This dissertation will focus on the busulfan metabolite EdAG that is suggested to be
reactive towards biological nucleophiles due the electrophilic dehydroalanine residue. The
potential reactivity of EdAG could be implicated in a number of disease states where GSH
depletion or macromolecular conjugation is associated, such as hepatic veno-occlusive disease.

2.1.3

Hepatic Veno-Occlusive Disease Associated with Busulfan
Hepatic veno-occlusive disease, or HVOD, is caused by the destruction of sinusoidal

endothelial cells (SECs) resulting from myeloablative conditioning therapies of busulfan and
cyclophosphamide during bone marrow and hematopoietic stem cell transplants. Prior to
therapeutic drug monitoring, anywhere between 30-50% of patients receiving busulfan
conditioning therapy developed HVOD, with a third of those having such a severe form that they
do not survive (16,30). HVOD is difficult to predict because oral administration of busulfan has
such a high interpatient variability in absorption and exposure. In myeloablative therapy,
busulfan is normally administered first, followed by a washout period of at least 24 hours, then
treatment with cyclophosphamide. Busulfan has been shown to deplete intracellular hepatic
GSH levels in murine models by as much as 50% (31) and it is known that the major metabolite
of the active form of the prodrug cyclophosphamide is detoxified by GSH, further depleting
GSH. Because both drugs require GSH for detoxification along with an oxidative environment
that could saturate GR-catalyzed GSSG reduction to GSH, it is logical that intracellular hepatic
GSH could be reduced to levels that are insufficient to protect the SECs in the liver.
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Busulfan causes a depletion in GSH stores due to its metabolism and renders hepatocytes
and SECs vulnerable to injury caused by the co-administered cyclophosphamide. It is uncertain
whether HVOD is caused by toxicity related to circulating busulfan or from busulfan
metabolites. However, Srivastava et al suggested busulfan metabolites as responsible for GSH
depletion and increasing the exposure of cyclophosphamide as a possible explanation for the
elevated risk of HVOD (32). Tetrahydrothiophene (THT) is the lipophilic metabolite of busulfan
that undergoes further oxidation by Cytochrome P450s and has been shown to be toxic to SECs
and hepatocytes, thus most research on busulfan-mediated HVOD has focused on THT. Clinical
trials involving busulfan-cyclophosphamide co-administration have found a correlation between
busulfan exposure levels and HVOD that would suggest a maximum busulfan exposure (<1,500
µmol x min/L) that greatly reduces chances of inducing HVOD (9). Therapeutic drug
monitoring after the first dose of busulfan is useful in determining busulfan exposure and allows
for dose adjustments to reduce risks of HVOD.
Therapeutic drug monitoring requires bioanalytical instrumentation to identify and
quantify busulfan and its metabolites in biological fluids in order to determine safe and effective
dosing and exposure limits. Typically, such instruments as high performance liquid
chromatography (HPLC) coupled to electrospray ionization mass spectrometry (ESI-MS), or
LC/MS, are employed. HPLC is used to separate analytes from salts and other impurities in the
matrix, while MS can structurally identify and quantify the analytes.

2.1.4

Electrospray Ionization Mass Spectrometry (ESI-MS)
A common ionization technique used with mass spectrometry when interfaced with liquid

chromatography is electrospray ionization (ESI), a soft ionization technique that ionizes analytes
24

in the solution phase before nebulization to the gaseous phase without degrading or denaturing
the analyte (33). ESI was first published by John Fenn in 1989 (34), but was the cumulative
work of many. The principles behind ESI were laid down by Lord Rayleigh in 1882, and then
fully realized into production by Malcolm Dole in 1968, who discovered that when there are
solubilized ions in a droplet, as the solvent evaporates and the droplet becomes smaller, the
charge density increases to a critical point where the droplet disperses into numerous smaller
droplets. This phenomenon is known as the Rayleigh limit, where Coulombic repulsion was
greater that surface tension and allowed the droplet to disperse into many tiny droplets (35). The
Rayleigh limit then applies to each offspring droplet and the process is repeated as the ionized
droplets are “sprayed” from the narrow-bore capillary needle.
Electrospray ionization can be applied to both positive and negative ions, however
positive ESI is more common due to the ability of nitrogen atoms to add protons, with the
majority of marketed pharmaceuticals possessing amide and amine functional groups, where the
oxygen atom of the amide is protonated. In positive ESI, a positive charge, usually 5 kV, is
applied to the cone and is usually called the cone or spray voltage. This serves to help repel the
positively-charged analytes in droplets away from the cone and towards the mass analyzer.
There also exists a counter electrode with either a small orifice or heated capillary, where a
negative charge of significantly lower voltage is applied to attract the cationic analytes. An inert
gas, usually nitrogen gas, is used as a sheath gas to desolvate the charged droplets on their way to
the mass analyzer.

2.1.5 ESI-MS with Ion Trap for structural analysis

25

Ion trap (IT) mass analyzers are commonly used in conjunction with ESI to separate and
analyze ions according to their mass to charge ratio (m/z). First invented in the 1950s, ITs are
about the size of a softball and contain three electrodes, where an entrance and exit electrode
surround a ring electrode. Together, these three electrodes apply a constant radio frequency (RF)
signal with steadily increasing amplitude along with a direct current (DC) to the ring electrode.
This forces the ions into an orbit that essentially “traps” the ions, with each ion traveling on its
own orbit according to its m/z ratio. Due to the kinetic energy associated with the ions, a
damping gas (typically helium) is applied in the ion trap to cool the ions to a stable oscillating
flight path or trajectory.
IT mass analyzers have the ability to eject all ions out of the mass analyzer except the ion
of interest, which can then be subjected to collision-induced dissociation (CID) by bombardment
with high energy helium atoms. Tandem mass spectrometry, or MS/MS, is frequently used to
study the structure of molecules. IT mass analyzers also have the ability to perform multi-stage
fragmentation (MSn), capable of fragmenting the same ion numerous cycles.

2.1.6

Chapter Goals
It has been logically assumed that EdAG is a degradation product of the major busulfan

metabolite resulting from Phase II conjugation to GSH catalyzed by glutathione S-transferase,
specifically isoform A1-1. When busulfan is metabolized by GSTA1-1, a sulfonium ion is
formed, γ-glutamyl-β-(S-tetrahydrothiophenium)alanylglycine, or GS+THT, that is unstable at
pH 7.4 and non-enzymatically degrades to THT and EdAG. While most research has focused on
THT, there is a lack of literature on EdAG as a metabolite from busulfan. Thus, it was desired in
this chapter to demonstrate that EdAG is a metabolite from GST-catalyzed busulfan conjugation
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with GSH using an in vitro model of human liver cytosol. First, a reference standard of EdAG
will be synthesized to better identify the compound formed under physiological reaction
conditions using LC/MS/MS.
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EXPERIMENTAL PROCEDURES

2.2.1 Materials
Glutathione, 1-chloro-2,4-dinitrobenzene (CDNB), secondary butanol, busulfan, Lcysteine, formic acid, DMSO, Tris buffer, pH 7.4, and Dowex-50W were purchased from SigmaAldrich (St. Louis, MO). Sodium bicarbonate, methanol (optima), acetonitrile (optima),
isopropyl alcohol, and hydrochloric acid were purchased from Fisher Scientific (Pittsburgh, PA).
All water used was deionized with a NANOpure® water purification system (Barnstead, San
Jose, CA). Pooled human liver cytosol (HLC) from multiple donors, containing all cytosolic
isoforms of GST (20 mg/mL total protein concentration) was purchased from BD Gentest
(Bedford, MA). All water used was deionized with a NANOpure® water purification system
(Barnstead, San Jose, CA).

2.2.2

Instrumentation
High-performance liquid chromatography (HPLC) was performed on a Shimadzu 10 Avp

binary pump HPLC system equipped with a UV/Vis detector (Shimadzu Scientific Instruments,
Columbia, MD). Mass spectrometry was performed using an electrospray ionization (ESI) ion
trap (IT) LCQ DECA (ThermoFisher Scientific, Waltham, MA), capable of multi-stage mass
spectrometry (MS, MS/MS, MS3). Structural information was obtained using nuclear magnetic
resonance (NMR) on a Varian 300 MHz broadband spectrometer (Varian, Palo Alto, CA).

2.2.3

Synthesis of γ-Glutamyldehydroalanylglycine (EdAG)

2.2.3.1 Synthesis of the Precursor S-(2,4-dinitrophenyl)-Glutathione (GS-DNB)
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EdAG was synthesized by the elimination of S-(2,4-dinitrobenzene) from S-(2,4dinitrophenyl)glutathione (GS-DNB). Thus, GS-DNB was first synthesized by the condensation
of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB) under basic conditions
based on a modified method from Patchornik (36). Equimolar solutions of GSH (3.07 g in 40
mL of 1 N NaHCO3; 10 mmol) and CDNB (2.02 g in 20 mL methanol; 10 mmol) were prepared
and CDNB was added dropwise to GSH over 30 minutes with stirring. The solution was stirred
at room temperature for one hour and then filtered to eliminate precipitates. The product was
precipitated from solution by addition of 1 M HCl and collected by vacuum filtration, dried
overnight in a vacuum desiccator, and recrystallized from hot water. To ensure the correct
product was obtained, the yellow crystals were characterized by ESI-MS (m/z 474), MS/MS (m/z
399, MH+-glycine; m/z 345, MH+-pyroglutamic acid), melting point analysis (m.p. 189-191 ˚C)
and 1H NMR in d6-DMSO. The following 1H NMR resonances were monitored: δ 1.84 (m, 1H),
1.95 (m, 1H), 2.32 (m, 2H), 3.31-3.38 (m, 2H), 3.60-3.65 (m, 1H), 3.73 (m, 1H), 4.61 (m, 1H),
7.97 (d, 1H), 8.46 (d, 1H), 8.71 (d, 1H), and 8.87 ppm (m, 2H).

2.2.3.2 Synthesis of EdAG from GS-DNB
S-(2,4-Dinitrophenyl)glutathione was used as a precursor to γglutamyldehydroalanylglycine (EdAG) based on a modified method from Carthew et al (37).
Two grams of GS-DNB were dissolved in 100 mL of 0.5 M NaOH and stirred for 30 minutes at
room temperature. To remove impurities, the solution was extracted with 40 mL butanol and
repeated a total of 5 times. The combined aqueous layers were diluted to 300 mL and
approximately 15 grams of activated Dowex®-50W ion exchange resin (hydrogen form) was
added to remove sodium ions. The Dowex® was activated by dissolving the resin in 1 M HCl
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and dried. The pH of the solution dropped from 13 to 3.0, indicating exchange of H+/Na+. The
aqueous solution was evaporated using either roto-evaporation or speed vacuum evaporation to
collect a light brown solid. The obtained product was characterized by LC/MS/MS by the
observance of a single absorbance peak at 254 nm corresponding to parent ion m/z 274 that was
fragmented (MS/MS) to obtain characteristic daughter ions (m/z 256, MH+-water; m/z 199, MH+glycine; m/z 145, MH+-pyroglutamic acid). 1H NMR in D2O was also performed and the
following peaks were monitored: δ 2.06 (m, 2H), 2.48 (m, 2H), 3.69 (m, 1H), 3.93 (s, 2H), and
5.76 (d, 2H). LC/MS/MS conditions performed were as follows: A Thermo Hybercarb column
(100 x 2.1 mm I.D., 5 µm, ThermoFisher, Waltham, MA) was used to isolate the product from
other constituents in the reaction mixture. A gradient of mobile phase A (0.5% formic acid in
90/10, v/v, water/acetonitrile) and mobile phase B (0.1% formic acid in 50/50, v/v,
isopropanol/methanol) at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7
minutes, 0→50% B; from 7-9 minutes, 50→0% B; and from 9-15 minutes, 100% A. An ESI ion
trap mass spectrometer was operated in the positive ion MS/MS mode with a spray voltage of 5.2
kV, capillary voltage of 30 V, capillary temperature of 300 ºC, a nitrogen sheath gas flow rate of
80 arbitrary units, and a selected reaction monitoring on m/z 274 (± 1.5 amu) with 30% collision
energy.
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Scheme 2.1

Synthesis of EdAG from GSH and CDNB

2.2.3.3 Formation of EdAG from S-Nitrosylated GSH (GSNO)
GSNO has the potential to degrade into EdAG by the elimination of S-NO (S-nitric
oxide). This could serve as a more efficient precursor to EdAG than GS-DNB without the
hydrophobic impurities. The stability of GSNO under various pH conditions was assessed with
the hypothesis that at high pH, the GSNO will lose S-NO and EdAG will remain. Controls of
GSH, NEM (trap GSH for more stable signal in LC/MS), and EdAG were incubated for 24 hours
in a 37 °C water bath in 100 mM Tris buffer, pH 8.4. Aliquots were taken every hour for the first
six hours, then again at 24 hours to determine baseline changes in stability using LC/MS, with
GS-NEM serving as an internal standard. Then, GSNO and NEM were incubated over 24 hours
and samples analyzed the first 5 hours and then again at 24 hours. The decrease in GSNO signal
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relative to EdAG was monitored to determine extent of GSNO degradation to EdAG. The
presence of GS-NEM indicates that GSNO degraded to GSH, which was trapped by NEM. If
GSNO was degrading to EdAG, the ratio of GSNO/EdAG would decrease. LC/MS in the
positive electrospray single ion monitoring mode was used to determine relative quantities of the
ions m/z 433, m/z 337, and m/z 274, corresponding to GS-NEM, GSNO, and EdAG, respectively.
Chromatographic separation was achieved using a gradient of mobile phase A (0.5% formic acid,
0.1% trifluoroacetic acid in water) and mobile phase B (0.1% formic acid, 0.1% trifluoroacetic
acid in 50/50, v/v, methanol/water) as follows: 0→15 min, 0→40% B; 15→17 min, 40→100%;
and 17→20 min, 100→0% B. A Thermo Hybercarb column (100 x 2.1 mm I.D., 5 µm,
ThermoFisher, Waltham, MA) was used to separate the constituents in the incubation with a flow
rate of 200 µL/min. The first mass spectral scan event employed two simultaneous single ion
monitoring (SIM) scans of m/z 274 (for EdAG) and m/z 337 (for GSNO) and was performed
from 0→12 min. The second scan event was a single SIM on m/z 433 (for GS-NEM) from
12→20 min.
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Scheme 2.2

2.2.4

Synthesis of EdAG from GSNO

Identification of EdAG after in vitro busulfan metabolism
Busulfan (0-5 mM) was incubated with human liver cytosol (total protein 1.0 mg) in the

presence of 1.0 mM GSH in 100 mM Tris buffer (pH 7.4, total volume 1.0 mL). Busulfan was
dissolved in DMSO and the total DMSO concentration was less than 1.0% (v/v). The mixture
containing human liver cytosol and GSH in buffer was preincubated for 5 minutes in a water
bath maintained at 37 °C, and reactions started by the addition of busulfan. Changes in the levels
of GSH, the enzymatic product GS+THT, EdAG, and a nonreducible lanthionine thioether GSG
(from GSH conjugation to EdAG) were monitored by liquid chromatography-mass spectrometry
(LC/MS). Chromatographic separation of the polar compounds was achieved using a Thermo
Hypercarb column (100 x 2.1 mm I.D., 5 µm particle size) (ThermoFisher, Waltham, MA). A
gradient of mobile phase A (0.5 % formic acid in 90/10, v/v, water/acetonitrile) and mobile
phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol) at 0.2 mL/min was run from 0-5
minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9 minutes, 50→0% B; and from 933

15 minutes, 100% A. The following ions were monitored: m/z 308, m/z 362, m/z 274, and m/z
581, corresponding to reduced GSH, GS+THT, EdAG, and GSG respectively. The structure of
EdAG was confirmed using LC/MS/MS in a separate run that fragmented m/z 274 to monitor
product ions of m/z 256, 199, and 145, consistent with neutral losses of water, glycine, and
pyroglutamic acid, respectively, based on a comparison of the mass spectrum and retention time
of the metabolite with that of the chemically synthesized standard. The structure of GSG was
also confirmed in a separate LC/MS/MS..
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RESULTS

2.3.1

Synthesis of γ-Glutamyldehydroalanylglycine (EdAG)
EdAG was successfully synthesized from GSH and CDNB according to the method of

Asquith and Carthew (37) modified by Younis et al (29). Typical product yields of the
precursor, S-(2,4-dinitrophenyl)glutathione (GS-DNB), ranged from 54-85% after
recrystallization. ESI-MS was performed to confirm product identity by monitoring the
molecular ion m/z 474 (Figure 2.3.1). Tandem mass spectrometry (MS/MS) was also performed
for structural identification and the product ions of m/z 345 and m/z 399 were formed,
corresponding to the MH+ GS-DNB molecular ion with neutral losses of pyroglutamic acid and
glycine, respectively (Figure 2.3.2).

Figure 2.3.1

ESI-MS of GS-DNB
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Figure 2.3.2

MS/MS of GS-DNB

EdAG was then synthesized from GS-DNB by addition of 0.5 M NaOH to induce a basecatalyzed β-elimination of the 1-S-(2,4-dinitrobenzene), followed by purification steps. Typical
yields ranged from 5-20%. The structure of EdAG was determined first by proton nuclear
magnetic resonance (1H NMR) in deuterium oxide (D2O), where the two vinylic protons of the
dehydroalanine moiety resonate as a doublet at 5.76 ppm (Figure 2.3.3). The resulting 1H NMR
spectrum is comparable to previous spectra that were fully characterized (29).
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Figure 2.3.3

1

H NMR of EdAG

The purity of EdAG was determined by LC/MS/MS, where the presence of a single peak in both
the UV254nm absorbance and the MS/MS spectrum suggested EdAG is the major constituent
present (inset of Figure 2.3.4). Tandem mass spectrometric (MS/MS) structural confirmation
was determined on the EdAG ion at m/z 274 that produced the daughter ions m/z 145, m/z 199,
and m/z 256, corresponding to the MH+ EdAG molecular ion with neutral losses of pyroglutamic
acid, glycine, and water, respectively (Figure 2.3.4).
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Figure 2.3.4

2.3.2

LC/MS/MS Identification of EdAG

Formation of EdAG from S-Nitrosylated GSH (GSNO)
EdAG synthesis could occur via an alternate mechanism by the potential loss of S-nitric

oxide (S-NO) from S-nitrosylated glutathione (GSNO). S-Nitrothiols are stable carriers of nitric
oxide (NO), of which S-nitrosylated glutathione is one of the most abundant. SNitrosoglutathione, or GSNO, is capable of transporting NO as well as transporting GSH to
induce such reactions as protein S-nitrosylation and S-glutathionylation (38). S-Nitrosylated
proteins are formed from transnitrosylation of NO from GSNO to cysteine residues on proteins.
S-Glutathionylation of proteins could be formed from degradation of GSNO to EdAG, through
the loss of S-NO, and subsequent conjugation of EdAG by a cysteine residue. The
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aforementioned chemical synthesis of EdAG involved removal of hydrophobic impurities
resulting from the 1-S-(2,4-dinitrobenzene) moiety that has relatively poor yield. It was
hypothesized that GSNO could lose S-NO to form EdAG under similar alkaline conditions in a
much cleaner synthesis procedure with potential higher product yields. The stability of GSNO
was determined by incubation for 24 hours in a 37 °C water bath in Tris buffer, pH 8.4, which
were optimal degradation conditions for GSNO (39). More alkaline conditions (pH > 9) resulted
in poor mass spectra with the absence of any recognizable molecular ion. Three separate single
ion monitoring scans were performed for GS-NEM, GSNO, and EdAG. No external EdAG was
added, thus any EdAG detected was from GSNO degradation to EdAG and S-NO. Figure 2.3.5
displays the GSNO degradation after 24 hours, where a substantial amount of GSNO degraded to
GSH, which was immediately trapped by NEM to form GS-NEM (m/z 433; bottom panel). A
very small, insignificant amount of GSNO degraded to EdAG (m/z 274; top panel), which
demonstrated the inability of GSNO to be a reliable precursor for EdAG chemical synthesis on a
large scale. The majority of GSNO remained stable after 24 hours (m/z 337; middle panel).
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Figure 2.3.5

2.3.3

LC/MS of GSNO 24 hour degradation

Identification of EdAG after in vitro Incubation of Busulfan with Human Liver

Cytosol
A mass spectrometric detection method was developed to determine if EdAG is a
metabolite of busulfan by human liver enzymes. Busulfan was incubated with GSH and human
liver cytosol, which contains the major soluble isoforms of GSTs that would normally be present
in hepatocytes, under physiological conditions of pH 7.4 and 37 °C. The presence of busulfan
metabolites was determined by LC/MS analysis after 2 and 24 hours. Figure 2.3.6 contains
panels A, B, C, and D that monitored the molecular ions m/z 308, m/z 362, m/z 274, and m/z 581,
corresponding to reduced GSH, GS+THT, EdAG, and GSG, respectively. Through two hours of
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incubation, busulfan-GSH conjugation catalyzed by GSTs formed the unstable sulfonium
GS+THT (Panel B) with excess GSH (Panel A) remaining in solution. The EdAG (Panel C)
formed, resulting from spontaneous degradation of GS+THT, was immediately conjugated
through nucleophilic addition by GSH in solution to form the non-reducible thioether (or
lanthionine) GSG (Panel D).

A

B

C

D

Figure 2.3.6

Busulfan Incubation with Human Liver Cytosol after 2 hours incubation
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Through the next 22 hours, the GSTs continued to conjugate busulfan with GSH to form
GS+THT, which slowly degraded to EdAG at pH 7.4 and 37 °C. After 24 hours, the GSH in
solution was depleted due to enzymatic busulfan conjugation, nonenzymatic conjugation of
EdAG to form GSG, or oxidation to GSSG (not shown). Figure 2.3.7 demonstrates the depletion
of GSH (Panel A), however GS+THT (Panel B) was still abundant because of its slow
degradation at pH 7.4. GS+THT degraded much faster at pH 8.4 than under physiological pH
conditions as shown by previous work in our lab (29). Due to depletion of GSH and continual
degradation of GS+THT to EdAG, EdAG (Panel C) was allowed to accumulate as there was little
or no GSH to trap EdAG to form GSG (Panel D). EdAG was thus shown to be a busulfan
metabolite from GST-catalyzed glutathione conjugation.
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A

B

C

D

Figure 2.3.7

Busulfan Incubation with Human Liver Cytosol after 24 hours incubation
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DISCUSSION

2.4
Mass spectrometry is a powerful analytical tool with the ability to elucidate structural
information from compounds. ESI is a soft ionization technique that allows molecules to stay
intact for analysis of the molecular ion (MH+). Ion trap mass analyzers have the ability to
fragment the molecular ion through numerous cycles using multi-stage mass spectrometry (MSn),
which can help elucidate the structure by studying neutral losses from the MH+ and its product
ions. This technology was useful for determining the structure and purity of the synthesized γglutamyldehydroalanylglycine (EdAG) from GSH and CDNB.
The first step in the synthesis of EdAG was the formation of the dinitrophenyl-Sconjugate of glutathione. This was performed by mixing equimolar solutions of GSH and 1chloro-2,4-dinitrobenzene (CDNB) slowly and providing ample time and mixing to ensure
complete conjugation. This product was subsequently purified by precipitation from solution
and recrystallization from hot water. This reaction is relatively efficient, with product yields
typically ranging from 54-85%. Caution must be taken in regards to contact and inhalation of
CDNB and GS-DNB. In order to determine whether the bright yellow product was in fact GSDNB, ESI-MS/MS was employed to elucidate the structure. GS-DNB is insoluble in water, thus
methanol was used to dissolve GS-DNB crystals with 0.1% formic acid. An intense signal at m/z
474 appeared, corresponding to the molecular ion (Figure 2.3.1). Fragmentation of the MH+ was
performed using CID to study the product ions to ensure validity of the structure. Because GSDNB contains a GSH backbone consisting of glutamate, cysteine, and glycine residues, the
typical neutral losses by CID associated with GSH were expected, such as the losses of water,
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glycine, and pyroglutamic acid. Indeed, fragmentation by CID of GS-DNB showed neutral
losses of glycine and pyroglutamic acid (Figure 2.3.2). Pyroglutamic acid is a common neutral
loss for GSH-containing compounds when analyzed by ESI-MS/MS (40,41). This suggested that
the major constituent in the bright yellow product was GS-DNB with a MH+ of m/z 474.
From GS-DNB, EdAG was formed by adding strong base (0.5 M NaOH) to facilitate the
β-elimination of 1-S-(2,4-dinitrobenzene) and leaving the tripeptide γglutamyldehydroalanylglycine, or EdAG. The bright yellow crystals dissolved in the base
rapidly and the color of solution quickly turned to a dark amber and eventually to a deep
orange/brown color over the 30 min stir. To remove the hydrophobic impurities responsible for
the dark color, secondary butanol was added to extract the impurities from the aqueous solution
of EdAG. The remaining aqueous layer was reduced in volume by approximately 50% by the
slightly polar nature of sec-butanol and accounting, at least partly, for the poor product yield.
The dilution of the aqueous layer to 300 mL with deionized water allowed for a more efficient
ion exchange to occur by the Dowex® H+/Na+ exchange resin, which dropped the pH of the
solution from 13 to 3. After evaporation, there was a light brown, water soluble solid. 1H NMR
and LC/MS/MS confirmed the structure of the major constituent of the product.
The 1H NMR showed the presence of the two vinylic protons associated with the
dehydroalanine moiety of EdAG, suggesting that EdAG was the major product formed. High
performance liquid chromatography (HPLC) interfaced with tandem mass spectrometry
(LC/MS/MS) was then performed to determine the presence of UV-detected impurities with a
signal in the mass spectrum in the range of m/z 100-1000. The UV chromatogram showed only
one major peak at 254 nm, which corresponded to EdAG at m/z 274 as indicated by the unique
MS/MS fragmentation pattern corresponding to EdAG (Figure. 2.3.4). The mass spectrum did
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reveal other impurities present in the aqueous solution of product, particularly the sodium adduct
of EdAG at m/z 296. There were other ions present in the mass spectrum, but they were minor
products compared to EdAG. It was concluded that EdAG was successfully and sufficiently
synthesized for use in future experiments.
The anticancer agent busulfan is commonly used to treat chronic myelogenous leukemia
(2,3), polycythemia rubra vera (5), essential thrombocythemia (6), and in high dose therapy, coadministered with cyclophosphamide, as conditioning therapy prior to hematopoietic or bone
marrow stem cell transplants (4). The major route of busulfan metabolism is glutathione
conjugation catalyzed by GSTA1-1 in the cytosol of hepatocytes (27) to form the unstable
sulfonium GS+THT as shown in Scheme 1.1. The sulfonium nonenzymatically degrades to THT
(26) and the dehydroalanine analog of glutathione, EdAG (29). As long as GSH is present,
electrophiles such as EdAG can be conjugated and detoxified. However during high dose
busulfan administration, e.g. bone marrow transplant conditioning therapy, GSH can become
depleted and render the cell vulnerable to reactive electrophiles. The amount of EdAG produced
is directly proportional to the amount of metabolized busulfan, however that exact amount is
nearly impossible to quantitate. It is assumed that intrahepatocellular concentrations of EdAG
are not nearly as great as the millimolar concentrations of intracellular GSH. However the
increased oxidative stress state of the liver could be associated with depletion of reduced GSH by
oxidation to GSSG.
Busulfan has been shown to deplete intracellular hepatic GSH levels in vitro in murine
models by as much as 50% (31) and it is known that the major metabolite of the active form of
the prodrug cyclophosphamide (4-hydroxycyclophosphamide) is detoxified by GSH, further
depleting GSH. In myeloablative therapy, busulfan is normally administered first, followed by a
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washout period of at least 24 hours, then treatment with cyclophosphamide. Because both drugs
require GSH for detoxification, it is logical that intracellular hepatic GSH could be reduced to
levels similar to those of the electrophilic compounds requiring GSH conjugation. A major
concern during this combination therapy is the potential onset of hepatic veno-occlusive disease
(HVOD). HVOD occurs in zone 3 of the centrilobular region of the liver, which contains the
highest hepatocyte concentrations of the drug metabolizing enzymes (DMEs) of cytochrome
P450s and GSTs (42). As a busulfan metabolite formed from GSTs, EdAG could be
contributing to HVOD by inhibiting GSTs, or trapping GSH directly, resulting in increased
busulfan exposure. EdAG could also be contributing to HVOD by inhibiting GSTs producing
more circulating busulfan as will be demonstrated in a later chapter.
After incubation of busulfan, GSH, and human liver cytosol under physiological
conditions, EdAG was detected by LC/MS as a busulfan metabolite. After 2 hours, most EdAG
formed was immediately trapped by unreacted GSH to form GSG. This observation is consistent
with the nonenzymatic and spontaneous conversion of GS+THT to EdAG and supports the
electrophilic nature of the dehydroalanine-containing EdAG intermediate. However, after 24
hours of continuous busulfan conjugation catalyzed by the cytosolic GSTs in human liver
cytosol, reduced GSH levels became depleted and EdAG was continually being formed by
spontaneous degradation of GS+THT. With limited GSH reserves to form GSG, EdAG
accumulated. This evidence suggested that EdAG is a busulfan metabolite from in vitro
metabolism. Mass spectrometry has been known to form dehydroalanine residues from cysteines
and serines through CID prior to the ion hitting the mass analyzer (43). The evidence of the
accumulation of EdAG after 24 hours incubation suggests that the EdAG detected by LC/MS
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was not a byproduct of inadvertent mass spectrometric CID, but rather EdAG formation in
solution by degradation of GS+THT to EdAG and THT.
In conclusion, this dissertation work has thus far demonstrated that EdAG can be
successfully synthesized from a conjugate of glutathione (GS-DNB) and that EdAG is an in vitro
busulfan metabolite. The next chapter will study the reactivity of EdAG towards cellular thiols.
The amino acid L-cysteine, the cysteine-containing tripeptide glutathione (GSH), and protein
models (bovine insulin and serum albumin) containing reactive cysteine residues will be
incubated with EdAG to determine the extent of conjugation
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Chapter 3

Conjugation addition reactions of the
dehydroalanine analog of GSH toward cellular
thiols
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INTRODUCTION

3.1

Reactivity of Dehydroalanines

3.1.1

EdAG is a dehydroalanine analog of Glutathione
Glutathione (GSH) is the most prevalent low molecular weight cellular thiol in

mammalian cells. In addition to a major cellular role in oxidative status, there is an important
function of GSH in sequestering toxic, electrophilic xenobiotics (1). Nucleophilic reactivity of
GSH is based on conjugation of its thiol group with electrophilic compounds (2). Conjugation
with GSH can either be nonenzymatic nucleophilic addition or catalyzed by the glutathione-Stransferase (GST) superfamily of enzymes. There are numerous isoenzymes of GSTs, classified
into cytosolic (soluble), membrane, or mitochondrial. There are eight major families of
mammalian GSTs (alpha, zeta, theta, kappa, mu, pi, sigma, and omega) (3). Dehydroalanine
(Dha) residues are formed posttranslationally mostly by a β-elimination of serine and threonine
residues, but also occurs less readily on cysteine residues. Dha-containing peptides react as
Michael acceptors that link cysteine residues with dehydroalanine groups to generate nonreducible thioethers as a posttranslational modification (4).

3.1.2

Reactivity of Dehydroalanine Moieties within Proteins
Dehydroalanine residues are common post-translational modifications within many

proteins, not just lantibiotics. In these settings however, the presence of Dha residues are most
likely a sign of oxidation or damage such that the protein is no longer functional. For
dehydroalanines to be formed within proteins, either serine/threonine or cysteine residues must
be dehydroxylated or dethiolated, respectively. This occurs most frequently during food
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processing under the intense heat and alkali conditions that favor the β-elimination of
cysteine/serine side chains to form the Dha. Also, an in situ alkaline condition (i.e. nearby basic
amino acids) can also promote the β-elimination to Dha. The cysteine-to-Dha transformation has
been studied in vitro in somatostatin, insulin, and transthyretin (5,6). When proteins are studied
by mass spectrometry, the formation of Dha could be caused by instrument itself and essentially
be artefactual of Dha formation in vivo (7).
One common plasma protein that is heavily involved in many physiological processes
that Dha formation occurs on is human serum albumin (HSA). HSA is a protein that contains 35
cysteine residues, 34 of which are involved in disulfide bonds leaving one free cysteine at
residue position 34. Human serum albumin has been studied to determine whether the any Cysto-Dha transformation is the result of a post-translational modification in vivo, the result of food
processing, or some other ex vivo factor such as incidental collision-induced dissociation of the
cysteine thiol side chain in the mass spectrometer. The existence of the Cys487-to -Dha
biotransformation on both commercially-purchased HSA and plasma HSA confirmed that the βelimination occurred as a post-translational modification in vivo (8). The presence of a Dha on
residue position 487 of HSA is indicative of the biotransformation of Cys487-to-Dha and the
oxidation of the protein, which makes it vulnerable to degradation by proteinases because of the
changes in secondary and tertiary protein structure (9).
Another set of proteins in which dehydroalanine residues are present are human lens
proteins. It has been demonstrated that Dha residues exist in many water soluble and insoluble
human lens proteins (10,11). The formation of Dha residues originated from either cysteines or
serines (phosphoserines) that underwent a hydroxide-mediated β-elimination (4,11,12). Aged
lens proteins tend to have more Dha residues than younger lens proteins. When there are nearby
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cysteines, histidines, or lysines within the same protein or adjacent proteins, lanthionines,
histidinoalanines, and lysinoalanines form, respectively (13). The formation of lanthionines are
favored not because of the presence of more cysteines than histidines or lysines, but the presence
of glutathione within the human lens (up to 2 mM) (14). GSH can form disulfide bonds (R-S-SR) with existing cysteine residues on proteins or non-reducible thioethers (R-S-R) with Dha
residues, both of which could result in the aggregation of proteins that lead to cataracts, which
are more prominent in aged lens proteins because of the incidence of Dha residues (10,15).
There are numerous other examples of Dha residues within specific proteins that play a
role in altering that protein’s function, such as casein, thiostrepton, human plasma mannanbinding lectin, and histidine ammonia lyase (16-19). Dehydroalanines have also been
synthesized within peptides to utilize their reactive properties to study protein interactions or to
act as inhibitors (4,12,20-31).

3.1.3

Chapter Goals
It has previously been demonstrated that EdAG is a busulfan metabolite from an in vitro

phase II glutathione conjugation reaction catalyzed by soluble GSTs in human liver cytosol. It is
desired in this chapter to study the reactivity of the electrophilic EdAG towards cellular
nucleophiles such as GSH, L-cysteine, and cysteine residues in proteins. Nucleophilic addition
of these thiol-containing nucleophiles with the electrophilic EdAG has the potential to form the
non-reducible lanthionine, or thioether, bridge (R-S-R).
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EXPERIMENTAL PROCEDURES

3.2.1

Materials
L-Cysteine, formic acid, GSH, and Tris buffer, pH 7.4, tris-(2-carboxyethyl)phosphine

(TCEP), bovine insulin, bovine serum albumin (BSA), α-cyano-4-hydroxycinnamic acid, and
trypsin were purchased from Sigma-Aldrich (St. Louis, MO). Sodium bicarbonate, methanol
(optima), acetonitrile (optima), isopropyl alcohol, and hydrochloric acid were purchased from
Fisher Scientific (Pittsburgh, PA). Pooled human liver cytosol (HLC) from multiple donors,
containing soluble isoforms of GSTs (20 mg/mL total protein concentration) was purchased from
BD Gentest (Bedford, MA). All water used was deionized with a NANOpure® water
purification system (Barnstead, San Jose, CA).

3.2.2

Instrumentation
High-performance liquid chromatography (HPLC) was performed on a Shimadzu 10 Avp

binary pump HPLC system equipped with a UV/Vis detector (Shimadzu Scientific Instruments,
Columbia, MD). Mass spectrometry was performed using an electrospray ionization (ESI)
quadrupole ion trap (QIT) LCQ DECA (ThermoFisher Scientific, Waltham, MA), capable of
multi-stage mass spectrometry (MS, MS/MS, MS3). Matrix-assisted laser desorption ionizationtime of flight (MALDI-TOF) mass spectrometric analyses were performed on a Micromass
Reflectron MALDI-TOF, (Waters, Milford, MA).
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3.2.3

EdAG-Cysteine Adduct (S-[β-Alanyl]-glutathione) formed nonenzymatically
A solution of EdAG in water (1.0 mM) was mixed with a solution of L-cysteine (1.0 mM

in 100 mM Tris buffer, pH 7.4) in 100 mM Tris buffer, pH 7.4 (final volume, 1.0 ml). The
mixture was heated in a 37 °C water bath for 12 hours, with aliquots taken every hour to monitor
the reaction. Aliquots were further diluted 200-fold in a solution of 0.1% formic acid in
methanol/water (50:50, v/v), and the product was detected by electrospray mass spectrometry
(ESI-MS). The mass spectrum of the predicted protonated molecular species of m/z 395 was
consistent with the molecular weight of the cysteine-EdAG conjugate (S-[β-alanyl]-glutathione).
MS/MS fragmentation of this conjugate was performed under the CID conditions of 30%
collision energy and 1.5 amu window width. Further fragmentation of the major MS/MS
production was subjected to MS/MS/MS (MS3) with a collision energy of 40% and 1.5 amu
window width.

3.2.4

Conjugate Addition of EdAG with Glutathione
GSH (1.0 mM in 100 mM Tris buffer, pH 7.4) was mixed with an aqueous solution of

EdAG (1.0 mM) in 100 mM Tris buffer, pH 7.4, and the mixture was incubated in a 37 °C water
bath overnight to provide the GSH-EdAG adduct (GSG). Identification of GSG was structurally
determined by mass spectral analysis. The mass spectrum of the predicted component in the
reaction mixture should give a protonated molecular species ion at m/z 581, consistent with
molecular mass of the GSH-EdAG (GSG) conjugate. Tandem MS fragmentation was performed
on the MH+ ion of GSG in an ion trap mass spectrometer using a collision energy of 30% and a
1.5 amu window width.
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3.2.5

EdAG-Glutathione conjugation catalyzed by GSTs
GSH (1.0 mM in 100 mM Tris buffer, pH 7.4) was mixed with an aqueous solution of

EdAG (1.0 mM) in 100 mM Tris buffer, pH 7.4, and the mixture was incubated in a 37 °C water
bath for 12 h in the presence of 0.2 mg of human liver cytosol, which contains all soluble
isoforms of GSTs. Identification of GSG was made by LC/MS analysis and a qualitative
estimate of increased GSG abundance was determined from comparison of controls without
enzymes versus with enzymes. Chromatographic separation of the polar compounds was
achieved using a Thermo Hypercarb column (100 x 2.1 mm I.D., 5 µm particle size)
(ThermoFisher, Waltham, MA). A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v,
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol)
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9
minutes, 50→0% B; and from 9-15 minutes, 100% A. The mass spectrometer was operated in
the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30 V,
capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arb. units. The
following ions were monitored: m/z 274, m/z 308, and m/z 581, corresponding to EdAG, reduced
GSH, GSG, respectively. The signal intensity of GSG formed nonenzymatically was compared
to that of GSG formed in the presence of GSTs to determine if GSG conjugation was
significantly enhanced by catalysis by GSTs.

3.2.6

Reactivity of EdAG with Insulin
Bovine insulin (MW 5734 Da) consists of an A-chain and a B-chain that is connected by

two inter-chain disulfide bonds. The insulin was reduced to the B-chain (MW 3400 Da),
containing two reactive thiols, by addition of 5 mM tris-(2-carboxyethyl)phosphine (TCEP) to a
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2 µM solution of bovine insulin in deionized H2O, pH 2.0 (adjusted with 1 M HCl). The
reduction to the B-chain was complete within 2 hours and was monitored by both ESI-MS and
MALDI-TOF. As a positive control, the B-chain was then incubated with the electrophilic
Michael acceptor N-ethyl maleimide (NEM; MW 125 amu) to ensure that the two cysteine thiols
are reactive toward electrophiles with an expected MW of 3650 Da. Excess NEM (1 mM) was
used to ensure conjugation to both cysteine residues on reduced B-chain. Excess EdAG (1 mM)
was then incubated with unreacted B-chain to determine the extent of EdAG reactivity towards
cysteine residues on proteins, with an expected product of 3946 Da.

3.2.7

Reactivity of EdAG with Albumin
EdAG was reacted with a more biologically-relevant protein, serum albumin, to study the

reactivity toward the free cysteine residue. Bovine serum albumin (BSA) was used in lieu of
human serum albumin due to its availability and alkylation to both NEM and EdAG was
performed based on a modified method of Li et al (32). BSA (60 µM), containing 17 disulfide
bonds, was reduced with 50 mM TCEP and diluted to a volume of 500 µL with 100 mM Tris
buffer, pH 7.4, for 2.5 hours in a 55 °C water bath. After cooling, excess NEM or EdAG (400
mM) was added to reduced BSA for 2 hours, followed by filtration through Microcon 10 kDa
filters to remove excess TCEP and NEM or EdAG. Alkylated BSA was reconstituted with 500
µL of 100 mM NH4HCO3 buffer, pH 8.6 and a 1/20 (trypsin/BSA, w/w) amount of trypsin was
added to digest the alkylated BSA while incubated overnight in a 37 C water bath. The digestion
was quenched by the addition of 20% acetic acid. The expected BSA peptides from trypsin
digestion were determined from a protein BLAST search and entered into a spreadsheet. The
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peptides containing cysteine residues were added to the mass of either NEM or EdAG to account
for the expected MW of the modified residue. Many peptides contained more than one cysteine
residue. MALDI-TOF mass spectral analyses were performed by mixing the digest solution with
a solution of 10 mg/mL α-cyano-4-hydroxycinnamic acid in 0.1% formic acid in 90/10 (v/v)
ACN/H2O in a 1:1 manner (v/v). MALDI-TOF analyses were performed in the positive ion
mode with a full scan range of m/z 500-4000.
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RESULTS

3.3.1

EdAG-Cysteine Adduct (S-[β-Alanyl]-glutathione) formed nonenzymatically
Equimolar amounts of reduced L-cysteine and EdAG were incubated in Tris buffer, pH

7.4, and monitored by mass spectrometry to determine the extent of conjugation and the structure
of that adduct. A molecular ion at m/z 395 was found, which corresponded to the EdAGcysteine, or S-(β-alanyl)-glutathione, adduct. Tandem mass spectrometry was performed on m/z
395 and the major product ion formed was m/z 266, which corresponds to loss of pyroglutamic
acid, a typical neutral loss in collision-induced dissociation of glutathione-like compounds
(Figure 3.3.1). Minor product ions were formed from m/z 266 using multi-stage MS
(MS/MS/MS, or MS3) at m/z 248 and m/z 191, corresponding to neutral loss of water and
glycine, respectively, from the ion at m/z 266.
Because EdAG is achiral due to the 1,4-Michael conjugated system containing the
dehydroalanine moiety, the addition of nucleophiles such as GSH or L-cysteine to EdAG forms a
new chiral center. The probability exists that GSG consists of a pair of diastereomers, however
the stereochemistry of synthesized GSG and S-(β-alanyl)-glutathione was not determined.
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Figure 3.3.1

3.3.2

MS/MS Fragmentation Pattern of S-(β-Alanyl)-Glutathione

Conjugate Addition of EdAG with Glutathione
EdAG contains an α,β-unsaturated carbonyl system that adds nucleophiles, such as

sulfhydryl anions, to form a conjugate or adduct. Condensation of EdAG with the most
abundant cellular thiol GSH was performed under physiological conditions and yielded a
glutathione dimer analog with a non-reducible lanthionine cross-linkage (GSG). Tandem mass
spectrometry was performed on the GSG molecular ion m/z 581 to confirm the structure (Figure
3.3.2), where the product ions formed at m/z 323, m/z 452, and m/z 563 were from neutral losses
of two pyroglutamic acid molecules, one pyroglutamic acid, and water, respectively.
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Figure 3.3.2

3.3.3

MS/MS Fragmentation Pattern of GSG

EdAG-Glutathione conjugation catalyzed by GSTs
To determine if GSG formation was catalyzed by GSTs, the same solution was prepared

with equimolar amounts of reduced GSH and EdAG along with 0.2 mg of human liver cytosol,
which contained all soluble forms of GSTs. Aliquots were taken immediately, and then every
hour until GSG formation leveled off after 3 hours. Figure 3.3.3 demonstrates the presence of
EdAG and GSH at 5 minutes with minor nonenzymatic GSG formation having occurred. The yaxes are fixed to the relative abundance of the most intense signal of the three ions.
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EdAG

GSH

GSG

Figure 3.3.3

Nonenzymatic GSG formation after 5 minutes

Figure 3.3.4 demonstrates the changes in the relative abundance of the three ions after 180
minutes. GSG is now the most abundant ion present of the three after 3 hours. GSG formation
leveled off after 3 hours due to the depletion of reduced GSH, where most was involved in GSG
formation and the rest oxidized to form GSSG (data not shown).
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EdAG

GSH

GSG

Figure 3.3.4

Nonenzymatic GSG formation after 180 minutes

In the presence of human liver cytosol, containing soluble isoforms of GST including the
isoform most responsible for busulfan metabolism to EdAG (GSTA1-1), GSG formation was not
increased, indicating that EdAG is not a substrate for GSTs as hypothesized. Figure 3.3.5
demonstrates the formation of GSG in the presence of GSTs after 180 minutes, with relatively
less GSG formed than in the absence of GSTs after 3 hours.
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EdAG

GSH

GSG

Figure 3.3.5

3.3.4

GSG formation in presence of GSTs after 180 minutes

Reactivity of EdAG with Insulin
The reactivity of EdAG toward thiols was extended to cysteine residues within proteins.

Insulin is a relatively small protein containing 6 cysteine residues, with 4 on the A-chain and 2
on the B-chain. Within the A-chain, 2 cysteines are involved in an intra-chain disulfide bond and
the other 2 cysteines are each involved in separate inter-chain disulfide bonds with the 2
cysteines on the B-chain (Figure 3.3.6).
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Figure 3.3.6

Bovine Insulin

Electrospray ionization (ESI) and matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometry were both used to study both the multiply-charged ions and
the singly-charged protein molecular ion, respectively. MALDI mass spectrometry utilizes a
pulsed laser to softly ionize (not fragment) the analyte, while offering a higher mass range up to
8000 Da. Bovine insulin has a molecular weight of 5734 Da, which provides molecular ions
(and their charge states) of m/z 1147 (+5), m/z 1434 (+4), and m/z 1911 (+3) in ESI-MS (Figure
3.3.7). Intact insulin provides one molecular ion at m/z 5734 when analyzed by MALDI-TOF
(data not shown).
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Figure 3.3.7

ESI mass spectrum of intact bovine insulin

In order for the cysteine thiols to be reactive, the two inter-chain disulfide bonds must be reduced
by the reducing agent TCEP. Figure 3.3.8 depicts the ESI mass spectrum of the B-chain by the
ions at m/z 850 (+4), m/z 1134 (+3), and m/z 1700 (+2), along with TCEP at m/z 251. The
MALDI mass spectrum provides a single molecular ion for the B-chain at m/z 3400 with some
nonreduced, intact bovine insulin at m/z 5735 (Figure 3.3.9).
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Figure 3.3.8

ESI mass spectrum of bovine insulin B-chain
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Figure 3.3.9

MALDI mass spectrum of bovine insulin B-chain

To ensure the B-chain cysteine residues are reactive towards Michael acceptors, NEM
was incubated with B-chain. The ESI mass spectrum provides molecular ions at m/z 913 (+4),
m/z 1217 (+3), and m/z 1825 (+2), which corresponded to the B-chain conjugated to two
molecules of NEM, along with a TCEP-NEM adduct at m/z 376 (Figure 3.3.10). The singlycharged molecular ion of the B-chain+2NEM adduct was demonstrated to be m/z 3650 by
MALDI-TOF (Figure 3.3.11).
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Figure 3.3.10 ESI mass spectrum of the B-chain+2NEM adduct
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Figure 3.3.11 MALDI mass spectrum of the B-chain+2NEM adduct

Finally, EdAG was incubated with unreacted, reduced bovine insulin B-chain in order to
demonstrate that the electrophilic EdAG can react with thiols of cysteine residues on proteins.
The MALDI mass spectrum depicts a singly-charged molecular ion at m/z 3946 corresponding to
the B-chain conjugated to two molecules of EdAG; however most of the B-chain remained
unreacted at m/z 3400 (Figure 3.3.12). The multiply-charged molecular ions from ESI were not
clearly recognized (data not shown).
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Figure 3.3.12 MALDI mass spectrum of the B-chain+2EdAG adduct

3.3.5

Reactivity of EdAG with Albumin
The reactivity of EdAG with a cysteine-rich and physiologically-relevant protein,

albumin, was evaluated. Human serum albumin is one of the major plasma proteins responsible
for drug binding that is a marker of oxidative stress (33). Bovine serum albumin (BSA) was
used as an albumin model for reactivity toward EdAG. Several attempts to alkylate the lone free
cysteine at residue 34 of BSA with EdAG failed under a variety of reaction conditions, possibly
due to disulfide formation between the free thiols of two BSA molecules. To activate cysteine
thiols toward electrophiles, the thiol reducing agent TCEP was added to reduce all 35 cysteine
residues prior to incubation with excess EdAG or NEM (as positive control). Table 3.1 provides
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the relevant trypsin-digested BSA peptides containing cysteine residues that were alkylated by
EdAG.

Residues

Sequence

Unmodified

NEM-Modified

EdAG-Modified

581-587

CCAADDK

725.26

975.26

1271.26

499-507

CCTESLVNR

1024.46

1274.46

1570.46

460-468

CCTKPESER

1052.45

1302.45

1598.45

286-297

YICDNQDTISSK

1386.62

1511.62

1659.62

106-117

ETYGDMADCCEK

1364.48

1614.48

1910.48

375-386

EYEATLEECCAK

1388.57

1638.57

1934.57

Table 3.1

BSA peptides from trypsin digestion

Due to the abundance of modified peptides, only the most clearly recognizable EdAG-modified
peptides were presented to demonstrate the reactivity toward cysteine residues of albumin.
Figure 3.3.13 depicts the MALDI mass spectra of mass range m/z 1240-1300, where (A)
is NEM-alkylated BSA and (B) is EdAG-alkylated BSA. Both spectra contain signals at m/z
1249 and m/z 1283, which correspond to peptides that do not contain cysteine residues, and thus
are not modified in either incubation. Figure 3.3.13 A contains a signal at m/z 1274, which
corresponds to a 9-residue peptide from positions 499-507, that shows NEM-modified cysteines
that are unique to the NEM-alkylated BSA (also see Table 3.1). Figure 3.3.13 B contains a
signal at m/z 1271, which corresponds to a 7-residue peptide from positions 581-587. This
peptide is consistent with two EdAG-modified cysteines.
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A

B

Figure 3.3.13 MALDI mass spectra of mass range m/z 1240-1300
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Figure 3.3.14 depicts the MALDI mass range from m/z 1585-1675, where (A) is the
NEM-alkylated BSA and (B) is EdAG-alkylated BSA. Both spectra contain unmodified
peptides with signals at m/z 1590, m/z 1605, and m/z 1640. Figure 3.3.14 A contains a unique
12-residue peptide at m/z 1639 that contains two NEM-modified cysteines corresponding to
residues 375-386 (see Table 3.1). Figure 3.3.14 B contains two peptides unique to the EdAGalkylated BSA. The first is a 9-residue peptide from positions 460-468 with two EdAG-modified
cysteines, corresponding to m/z 1598. The second is a 12-residue peptide from positions 286297 with one EdAG-modified cysteine, corresponding to m/z 1661, although the expected mass
was 1659 amu. This 2 mass units difference was accepted because it was unique to the EdAGalkylated BSA solution and did not correspond to any unmodified peptides. It is not known if
the 2 Da difference represents a dehydrogenation reaction.
Figure 3.3.15 depicts the MALDI mass range from m/z 1880-1960, where (A) is the
NEM-alkylated BSA and (B) is EdAG-alkylated BSA. Both spectra contain unmodified
peptides at m/z 1889, m/z 1927, and m/z 1949. Figure 3.3.15 A contains a unique 16-residue
peptide from positions 508-523 with one NEM-modified cysteine corresponding to m/z 1948.
Figure 3.3.15 B contains two modified peptides that are unique to EdAG-alkylated BSA. The
first is a 12-residue peptide from positions 106-117 with two EdAG-modified cysteines,
corresponding to m/z 1911. The second unique peptide is a 12-residue peptide from positions
375-386 with two EdAG-modified cysteines, corresponding to m/z 1934.
The EdAG-modified peptides of trypsin-digested BSA, as well as bovine insulin, are
evidence of the formation of lanthionine bridges in proteins in vitro.
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A

B

Figure 3.3.14 MALDI mass spectra of mass range m/z 1585-1675
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A

B

Figure 3.3.15 MALDI mass spectra of mass range m/z 1880-1960
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DISCUSSION

3.4
Dehydroalanines occur frequently in nature, such as in albumin, human lens proteins, and
lantibiotics, as well as chemically during food processing. These dehydroalanines have been
shown to be reactive with cellular nucleophiles, most notably GSH, which subsequently forms a
non-reducible lanthionine bond.
The reactivity of dehydroalanines was analogous to the electrophilic dehydroalanine
analog of glutathione, EdAG, which is a metabolite of the anticancer agent busulfan. Both the
amino acid L-cysteine, which contains a nucleophilic side chain thiol, and the most abundant
form of cellular thiols, the tripeptide glutathione, were reacted with EdAG to determine the
extent of conjugation that occurs nonenzymatically. When equimolar amounts of EdAG and
either L-cysteine or reduced glutathione were incubated in solution under physiological
conditions of pH 7.4 and 37 °C, conjugation of the thiol to EdAG was detected by mass
spectrometry. Tandem mass spectrometry (MS/MS) was used, employing CID to confirm the
structure of each adduct to ensure the correct conjugate was formed. These experiments suggest
that the dehydroalanine moiety in EdAG is sufficiently reactive towards cellular thiols when
present as the individual amino acid cysteine or the tripeptide GSH. The non-reducible
lanthionine bond was formed by nucleophilic addition of a cysteine, either L-cysteine or GSH, to
a dehydroalanine residue in a tripeptide. Thus, EdAG could serve as a model peptide-containing
dehydroalanine to further study lanthionine formation in vivo.
Glutathione is a substrate for all GSTs and due to the high intracellular levels of GSH,
most cytosolic GSTs have GSH constantly bound in the hydrophilic glutathione binding site (G82

site). Hydrophobic substrates, such as busulfan, bind to the hydrophobic binding site (H-site),
which positions the substrate near the reactive thiol of GSH (actually the thiyl GS-) to induce
conjugation. EdAG was shown to bind GSTA1-1 on a GSH-agarose gel (34), but that does not
necessarily imply that EdAG is a ligand of either the G- or H-site. EdAG and GSH were
incubated in the presence of GSTs to determine if EdAG could bind the H-site and position itself
in close proximity to the reactive thiol of GSH in the G-site of GSTs such that GSG formation is
catalyzed by GSTs. After 3 hours, the reaction was complete and there was no significant
increase in GSG formation in the presence of GSTs relative to the nonenzymatic equimolar
incubation of EdAG and GSH. This outcome was expected because EdAG is a hydrophilic
molecule and probably doesn’t bind well or at all in the H-site, thus catalysis for GSG formation
is less likely.
The glutathionylation of proteins is a common post-translational modification (PTM),
which normally occurs when GSH attacks a cysteine or a dehydroalanine residue on a protein.
The dehydroalanine residue was originally either a cysteine or a serine that lost the heteroatom
functional group as a PTM. It was desired here to determine if EdAG could react with cysteine
residues on proteins to essentially glutathionylate the proteins, albeit in the reverse order with the
cysteine residue attacking the dehydroalanine of EdAG. Insulin was used as a model protein that
contains two reactive cysteine residues when reduced to its B-chain. Both electrospray
ionization (ESI), which produces multiply-charged molecular ions, and matrix-assisted laser
desorption ionization (MALDI), which produces singly-charged molecular ions, were used to
study the insulin conjugates with the Michael acceptors N-ethyl maleimide (NEM) and EdAG.
NEM is a well-known Michael acceptor and was used as a model electrophile to demonstrate the
ability of Michael acceptors to be conjugated by the reactive cysteine thiols of reduced bovine
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insulin B-chain. NEM proved to be an excellent model for Michael acceptors, with mostly all
the B-chain reacting with NEM. Because there are two reactive cysteine residues on each Bchain, there are two NEM molecules added to the B-chain, counting for an additional molecular
weight of 250 amu. When incubated in the same molar ratio to B-chain as in the NEM reaction,
EdAG also reacted with B-chain. Two EdAG molecules were conjugated per B-chain,
accounted for by the additional molecular weight of 546 amu. However, there was mostly
unreacted B-chain present in the MALDI mass spectrum (Figure 3.3.11), and the B-chain-EdAG
adduct was a minor product. This suggests EdAG is a reactive Michael acceptor, but not as
reactive as NEM. The evidence that EdAG is a relatively weak Michael acceptor is supported by
Li et al that suggested electron donation by the enamine functionality weakens the
electrophilicity of dehydroalanines in comparison with the electrophilicity of more classical
Michael acceptor compounds (35).
In conclusion, the electrophilic dehydroalanine analog of glutathione (EdAG) was shown
to be reactive towards the cellular nucleophiles L-cysteine, GSH, and cysteine residues on
bovine insulin B-chain and bovine serum albumin. This reactivity demonstrated the potential of
EdAG to trap intracellular GSH with a non-reducible thioether bond that could further deplete
GSH levels when the anticancer agent busulfan is administered. Also, EdAG has the potential to
bind cellular proteins and form non-reducible lanthionines that could alter their function and
disrupt cellular processes. One protein of particular interest that EdAG could react with is the
enzyme responsible for its formation, GSTA1-1. EdAG was shown to bind GSTA1-1 from
studies by Younis et al (34), however it was suggested that EdAG is not a substrate of the H-site
of GSTs, due to the lack of GST-catalyzed GSG formation. EdAG could however be a substrate
of the G-site due to its structural similarities to GSH, with the one obvious exception of the lack
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of the thiol group. In the next chapter, it was desired to determine the extent of EdAG binding in
the G-site and if EdAG could act as a competitive inhibitor of GSTs, particularly GSTA1-1
because it is the most abundant cytosolic GST isoform in the liver and is also the predominant
isoform responsible for EdAG formation from busulfan.
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Chapter 4

EdAG-Mediated Inhibition of Glutathione-S
Transferases
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INTRODUCTION

4.1.1

Glutathione-S Transferases (GSTs) Superfamily of enzymes
GSTs use reduced glutathione (GSH) to adduct electrophilic xenobiotics, such as

busulfan, to aid in their metabolism and elimination from the body. There are eight major
families of mammalian GSTs (alpha, kappa, mu, omega, pi, sigma, theta, and zeta) (1-5), where
the key residue for GSH activation is a serine for the theta class, but is a tyrosine for all others
(6,7). The tyrosine residue is acidic and helps stabilize the bound GSH to allow a basic residue,
suggested to be Arg15 (8), to activate the GSH by deprotonating the thiol group. The use of
Arg15 in forming the thiyl group is exclusive to isoform GSTA1-1. These interactions lower the
pKa of the GSH thiol group from 9.0 to a range between 6.9-6.0, allowing the formation of the
thiyl conjugate (GS) at physiological pH 7.4 and causing a 200-300-fold rate increase in the
GSH-substrate conjugation (9,10). The structurally-conserved tyrosine for GST class alpha is
Tyr-9, class mu is Tyr-6, and class pi is Tyr-7 (6). GSTs allow glutathione to conjugate
electrophilic substrates, which in this case is busulfan. Although busulfan has been shown to be
metabolized by three of the major cytosolic isoforms of GSTs (alpha, mu, and pi), GSTA1-1 is
the predominant isoenzyme responsible due to its high abundance in liver (11).

4.1.2 GST A1-1
GSTA1-1 is a cytosolic enzyme existing as a homodimer, with each subunit containing
222 amino acids. GSTA1-1 has been shown to be the predominant isoenzyme responsible for
busulfan conjugation and metabolism (11). In addition to the predominant enzyme for busulfan
metabolism, GSTA1-1 is also the most abundant isoenzyme found in human liver comprising
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approximately 3% of soluble proteins in human hepatocytes (2,12). Each of the two subunits in
the homodimeric GSTA1-1 contain a catalytic site, consisting of a hydrophilic GSH-binding site
(G-site), and a hydrophobic substrate-binding site (H-site), where the hydrophobic busulfan
binds. GSTA1-1 is known to metabolize a wide variety of different hydrophobic substrates due
to its substrate promiscuity (13). The topography of the H-site determines the substrate
specificity among the various isoenzymes of the cytosolic GST family (14). There also exists an
intersubunit solvent-accessible cleft on most GSTs. On GSTA1-1, the cleft is predominantly
positively charged and has been shown to have greater affinity towards hydrophilic, multivalent
negatively charged compounds (15). Among the substrates believed to bind this cleft are
bilirubin (16,17) and steroids (18), where both have been shown to noncompetitively inhibit
through a mechanism involving binding a site other that the catalytic site.
EdAG has been previously shown to bind GSTA1-1 (19), although that does not
necessarily imply that EdAG is a ligand for GSTA1-1 in either of the two binding sites (G-, Hsite). Previous work in this dissertation has demonstrated that the reaction between EdAG and
GSH is not catalyzed by GSTs, even though GSH is a substrate of the enzyme. This indicated
that EdAG is not a substrate for the hydrophobic substrate binding site (H-site). Due to the
structural similarities of EdAG and GSH, it was hypothesized that EdAG could compete with
GSH for binding in the G-site and competitively inhibit GSTs, namely isoform GSTA1-1.
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EXPERIMENTAL PROCEDURES

4.2.1

Materials
GSH, 1-chloro-2,4-dinitrobenzene (CDNB), α-cyano-4-hydroxycinnamic acid, and Tris

buffer, pH 7.4, were purchased from Sigma-Aldrich (St. Louis, MO). All water used was
deionized with a NANOpure® water purification system (Barnstead, San Jose, CA). Pooled
human liver cytosol (HLC) from multiple donors, containing all cytosolic isoforms of GST (20
mg/mL total protein concentration) was purchased from BD Gentest (Bedford, MA). Pure
human recombinant GSTA1-1 (2.5 mg/mL) was purchased from US Biological (Swampscott,
MA). Microcon-10 filters (Millipore Corp., Billerica, MA) with a mass cutoff of 10 kDa was
used to retain GST from solution.

4.2.2

Instrumentation
Ultraviolet (UV) absorbance was measured on a Beckman DU 640 UV/Vis

spectrophotometer (Beckman-Coulter, Fullerton, CA). Matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) mass spectrometric analyses were performed on a
Micromass Reflectron MALDI-TOF, (Waters, Milford, MA).

4.2.3

Inhibition of GSTs in Human Liver Cytosol by EdAG
Inhibition of GST by EdAG was determined using a modified established GST activity

assay (20) using CDNB, GSH, and human liver cytosol (containing most soluble GST
isoenzymes) as the catalyst. CDNB (final conc 1 mM) in methanol (final methanol conc less
than 0.5%), and GSH (final conc 1 mM) in Tris buffer, pH 7.4 were mixed and diluted with
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water to a final volume of 2 mL before addition of human liver cytosol (final conc 10 µg
protein/mL) to start the reaction. The reaction was monitored over 5 min for the change in
absorbance at 340 nm. CDNB concentration was held constant at 1 mM to saturate the H-site,
while varying concentrations of GSH in the G-site to determine competitive inhibition at the Gsite with EdAG. Specific activities (or reaction velocities) were calculated as the velocity of
product S-(2,4-dinitrophenyl)glutathione, or GS-DNB, formed per unit of enzyme over 5 minutes
using the extinction coefficient of ε = 9.6 mM-1cm-1 (20) in the equation below.

dA340 nm / dT
v=

9,6mM −1
, where dA340nm/dt is the change in absorbance at 340 nm over time (5
[E]

minutes), and [E] is the enzyme concentration. Specific activity is expressed in µmoles/mg/min.
GSH concentrations were 0.01, 0.05, 0.1, 0.5, and 1.0 mM. EdAG concentrations were 0, 0.01,
0.1, 0.5 and 1.0 mM. Each experiment was performed twice and average velocities were plotted
by SigmaPlot 8.0 (Systat Software, Inc., Point Richmond, CA) to calculate kinetic parameters.

4.2.4 Inhibition of human GSTA1-1 by EdAG

Inhibition of GSTA1-1 by EdAG was determined using the same procedure as above
with CDNB, GSH, and pure recombinant human GSTA1-1 as the catalyst. CDNB (final conc 1
mM) in methanol (final methanol conc less than 0.5%), and GSH (conc ranging 0.01-1.0 mM) in
Tris buffer, pH 7.4 were mixed and diluted with water to a final volume of 2 mL before addition
of pure GSTA1-1 (final conc 62.5 ng/mL) to start the reaction. Specific activities (or reaction
velocities) were calculated as the velocity of GS-DNB formed per unit of enzyme over 5 minutes

95

using the extinction coefficient of ε = 9.6 mM-1cm-1 (20). EdAG-induced GSTA1-1 inhibition
was assayed at the same EdAG concentrations of 0, 0.01, 0.1, 0.5 and 1.0 mM.

4.2.5

Irreversibility of EdAG-mediated inhibition of GSTA1-1

Pure GSTA1-1 (1.25 µg) was exposed to varying amounts of EdAG for 30 min at room
temperature to allow for potential irreversible binding to occur based on a previous study (21).
The solution was then filtered through a Microcon-10 filter apparatus to remove unreacted
excess EdAG and retain GSTA1-1. To condition the filters before use, a pre-wash of 100 µL of
100 mM Tris buffer, pH 7.4 was performed with the filters centrifuged at 10,000 rpm (13,725 x
g) for 30 min in an Eppendorf Mini Spin mini-centrifuge (Eppendorf, Westbury, NY). After the
30 min incubation and pre-wash, the solution containing GSTA1-1 and EdAG was filtered by
centrifugation at 10,000 rpm for 45 min. The enzyme was recovered by reconstitution with 100
µL of 100 mM Tris buffer followed by a 30 min wash filtration of 100 µL of H2O. To the
recovered enzyme in buffer, GSH and CDNB (final concentrations 1 mM) were added and
diluted with water to a final volume of 2 mL. The reaction was monitored for 30 minutes to
assess enzyme activity by monitoring the change in UV absorbance at 340 nm. Positive controls
were incubated with 10 mM ethacrynic acid (EA). Negative controls were incubated without
EdAG, filtered and reconstituted with substrates, and velocities over 30 minutes were normalized
to 100% recovered enzyme activity. EdAG concentrations during pre-incubations were 0.01,
0.1, 1.0, and 10 mM. Experiments were performed in triplicate and the average percent
recoveries calculated. The means ± standard error of the means (SEM) were plotted and
significance was determined using a two-tailed, unpaired Student’s t-test, with p < 0.05 as
statistically significant.
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4.2.6

Proteomic analysis of the GSTA1-1/EdAG adduct

In order for EdAG to form a covalent adduct with GSTA1-1, pure GSTA1-1 (1.8 µM)
was mixed with 10 mM EdAG for one hour in 10 mM Tris buffer, pH 7.4. Excess, unreacted
EdAG was removed by filtration, as described above, and reconstituted in 80 µL of water.
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric
analysis in the positive ion mode was used to determine if GSTA1-1 experienced a mass shift of
273 Da, equivalent to the mass addition of one EdAG molecule. A control of unreacted GSTA11 was used to calibrate the MALDI MS signal at 25,730 Da.
To elucidate the potential residue of GSTA1-1 that is conjugated to EdAG, a trypsin
digestion was performed. Again, 1.8 µM GSTA1-1 was incubated with 10 mM EdAG for one
hour in 10 mM Tris buffer, pH 7.4, followed by filtration to remove excess unreacted EdAG.
The GSTA1-1 was reconstituted from the filters with 80 µL of 100 mM ammonium bicarbonate
buffer, pH 8.6 in order to optimize enzyme conditions for the trypsin digest. A 1 mg/mL
solution of trypsin was made in deionized water adjusted to pH 3.0 with 10 mM HCl. A 1/20
(w/w) addition of trypsin/GSTA1-1 was made to the reconstituted GSTA1-1 in 100 mM
NH4HCO3 and incubated in a 37 °C water bath overnight for 18 hours. The samples were mixed
with α-cyano-4-hydroxycinnamic acid as matrix (1:1, v:v), spotted and dried on MALDI plate
prior to analysis by a Micromass Reflectron MALDI-TOF mass spectrometer in the positive ion
mode. A protein BLAST search was performed to list expected peptides from tryptic digestion.
The peptide containing the cysteine residue will be monitored in control and with EdAG to
detect any modifications of that cysteine by EdAG.
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RESULTS

4.3.1

Inhibition of GSTs in Human Liver Cytosol by EdAG

The inhibitory effects of EdAG were first evaluated using soluble GST isoforms in
human liver cytosol by varying GSH and EdAG concentrations over a 100-fold range. The data
are consistent with enzyme inhibition or inactivation involving mechanisms other than simple
competitive processes. Figure 4.3.1 displays the Michaelis-Menton plot that suggests either
irreversible or noncompetitive inhibition. Human liver cytosol provided an in vitro model of in
vivo GST activity in liver.

Figure 4.3.1

GST inhibition by EdAG
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4.3.2 Inhibition of GSTA1-1 by EdAG

To determine the effect of EdAG on the major isoform of GST associated with EdAG
formation, inhibition studies with pure recombinant human GSTA1-1 were performed. Under
the same incubation conditions as for the cytosolic fraction experiments, recombinant human
GSTA1-1 was inhibited by EdAG in a manner that suggested either irreversible or
noncompetitive inhibition. The mechanism of inhibition as noncompetitive is in accordance with
the previous experiment involving all cytosolic isoforms of GSTs in human liver cytosol. The
apparent KM and apparent VMAX for the reaction shown in Table 4.1 provide a calculated IC50
value of 99.2 µM for inhibition of GSTA1-1 by EdAG.

[EdAG] (mM)

0

0.01

0.1

0.5

1

KMapp (µM)

85.8

131

177

67.8

79.7

VMAXapp

40.1

40.8

19.1

6.21

6.34

(µmoles/mg/min)

Table 4.1

Enzyme Kinetic Parameters for GSTA1-1 Inhibition by EdAG Support Mixed

Noncompetitive Inhibition

The results were not consistent with competitive inhibition at the G-site. The data were better
explained by a complex inhibitory mechanism, as likely to be expected for a two-substrate
enzyme, such as GST. The data support mixed noncompetitive inhibition based on unequal
values given for both KIC (523 µM) and KIU (252 µM), respectively representing binding
constants for competitive and uncompetitive inhibitors (22). The Michaelis-Menton plot is
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pictured in Figure 4.3.2 that suggests either irreversible or noncompetitive inhibition of GSTA11 by EdAG.

Figure 4.3.2

GSTA1-1 inhibition by EdAG

To further suggest noncompetitive inhibition, other kinetic diagrams were plotted such as
Lineweaver-Burk (Figure 4.3.3), and Hanes-Woolf (Figure 4.3.4) plots, that both suggested
noncompetitive inhibition based on the estimated extrapolated intersection point of the lines in
the negative x-axis and the unparallel lines. The slopes of both plots are equivalent to the inverse
of VMAX, and because VMAX is changing, so are the slopes.
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Figure 4.3.3

Lineweaver-Burke plot suggests noncompetitive inhibition of GSTA1-1 by EdAG
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Figure 4.3.4

Hanes-Woolf plot suggests noncompetitive inhibition of GSTA1-1 by EdAG

To determine if there is a preference for inhibition at the G- or H-site of GSTA1-1, the
enzyme assay was repeated holding GSH concentration constant at saturating levels (1.0 mM)
and varying concentrations of CDNB. Concentrations of EdAG near the IC50 of 99.2 µM
displayed negligible decreases in velocity, suggesting that EdAG binding was not occurring at
the H-site (Figure 4.3.5). The decrease in velocity when EdAG was 1 mM results from the same
GST inhibition observed in Figure 4.3.2, when all substrates and inhibitor were 1 mM. This
experiment strongly suggested that EdAG is binding a separate non-substrate binding, or
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ligandin, site that is neither the G-site where GSH binds nor the H-site where CDNB and other
hydrophobic xenobiotics bind.

Figure 4.3.5

4.3.3

EdAG not inhibiting at substrate binding site

Irreversible Inhibition of GST by EdAG

The potential for irreversible inhibition of GST by EdAG was evaluated. The MichaelisMenton kinetic profiles of noncompetitive and irreversible inhibitors are similar in that inhibition
is concentration-dependent and enzyme activity cannot be restored by increasing substrate
(GSH) concentration. To determine if EdAG is also an irreversible inhibitor, EdAG was
incubated at room temperature with GSTA1-1 in the absence of substrates to allow for
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irreversible binding to occur. Figure 4.3.6 shows that a 30-minute preincubation of EdAG at 10
mM concentration with GSTA1-1 in the absence of GSH and CDNB showed irreversible
inhibition. Inhibition by preincubation concentrations at or below 1 mM EdAG was not
observed after 30 minutes. As a control for irreversible inhibition, preincubation of GSTA1-1
with ethacrynic acid (10 mM) inactivated the enzyme irreversibly (23). Experiments were
conducted that demonstrated the binding reaction was complete after 30 minutes and no further
inhibition occurred with preincubation times up to 2 hours (data not shown). Preincubations in a
37 °C water bath compared to at room temperature also did not affect binding efficiency. Each
bar is the average percent recovered GSTA1-1 activity (n=3) ± SEM. A two-tailed, unpaired
Student’s t-test was used to calculate significant difference in % activity (* P value <0.05 for
reactions containing 10 mM EA versus 0.01-1 mM EdAG was considered statistically
significant).
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Figure 4.3.6

Irreversible inhibition of GSTA1-1 by EdAG and ethacrynic acid

Further experiments were performed to determine whether EdAG was covalently binding
GSTA1-1. GSTA1-1 is a homodimer, with each subunit containing a cysteine residue at position
112. The most likely alkylation site is at a cysteine residue of GST. In the native homodimer,
the two cysteines are located in the solvent-accessible cleft that forms between the two
monomers. Figure 4.3.7 depicts the native conformation of the GSTA1-1 homodimer with the
two cysteine residues (highlighted in green) courtesy of molecular modeling of the known crystal
structure by John Jett. The position of these cysteine residues in the solvent cleft could
determine the mechanism of GSTA1-1 irreversible inhibition by 10 mM EdAG. It was shown in
Chapter 4 that EdAG is noncompetitively inhibiting GSTA1-1 at lower concentrations (≤ 1 mM)
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at a site other than the catalytic sites (G-, H-site), and literature has demonstrated compounds
that noncompetitively inhibit by binding at the solvent cleft (16,17).

4.3.4

Proteomic analysis of the GSTA1-1/EdAG adduct

The irreversible inhibition of GSTA1-1 by 10 mM EdAG was further characterized to
determine if EdAG, an electrophilic compound previously shown to be conjugated by cysteine
residues in insulin and albumin, is being conjugated by one or both of the cysteine residues in the
solvent cleft. GSTA1-1 was preincubated with 10 mM EdAG for up to one hour before removal
of excess EdAG and reconstitution of GSTA1-1 in water for analysis by MALDI looking for an
intact total mass shift corresponding to EdAG adduction.

Figure 4.3.7

GSTA1-1 contains two cysteine residues in the solvent cleft

106

Compared to control GSTA1-1, no mass shift was detected by MALDI for incubations of
GSTA1-1 with ≤ 1 mM EdAG, which was expected. However, at 10 mM EdAG, a mass shift of
400+ Da was detected. The exact implications of this shift were not entirely clear, yet it
corresponds with Figure 4.3.6 that only the 10 mM EdAG incubation irreversibly inhibited
GSTA1-1.
To more fully characterize a potential alkylation of EdAG by GSTA1-1, a trypsin
digestion was performed prior to analysis by a Micromass Reflectron MALDI-TOF. Roughly 60
% of the expected tryptic peptides of GSTA1-1 were detected, but not the peptide containing the
cysteine residue at position 112. Thus, it was not possible to elucidate whether EdAG was
covalently adducted to Cys112. In the sample containing 10 mM EdAG, the same GSTA1-1
tryptic peptides were detected as in control, indicating that EdAG was not conjugated to any
other residues.
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DISCUSSION

4.4

The metabolism of the chemotherapeutic agent busulfan results in the formation of a
dehydroalanine analog of glutathione (EdAG) that contains an α,β-unsaturated system and
renders the molecule an electrophilic Michael acceptor. Although dehydroalanines are relatively
weak Michael acceptors because enamine intermediates contribute electron density to the
electrophilic site (24), EdAG does react with the Michael donors GSH and cysteine, forming a
thioether or lanthionine bond (19), as well as cysteine residues on insulin B-chain and serum
albumin, previously demonstrated in Chapter 3 of this dissertation. The reactivity of EdAG
toward proteins was extended to GSTs, which were previously indicated to bind GSTs and the
mechanism of inhibition from binding of EdAG was characterized.
GST transfers glutathione to electrophilic substrates by a ternary complex mechanism
(25). EdAG is an electrophilic compound that has been shown to bind GSTA1-1 (19). EdAG is
not a substrate for GST, yet acts as a GST inhibitor. When incubated with human liver cytosolic
fraction or pure recombinant human GSTA1-1, micromolar concentrations of EdAG
demonstrated mixed noncompetitive inhibition, with a predominantly uncompetitive mechanism
due to the value of KIU being lower than KIC as calculated by SigmaPlot. The apparent VMAX
decreased substantially in the presence of increasing concentrations of EdAG, while the apparent
KM values varied relatively less (Table 4.1), further indicating noncompetitive inhibition. Mixed
noncompetitive inhibition was suggested based on the observation of changes in both the
apparent VMAX and apparent KM. If only apparent KM changes, the mechanism is considered
simple competitive inhibition, and if only apparent VMAX changes, its pure noncompetitive.
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When both apparent VMAX and KM values change, it is considered mixed-type inhibition, and
because apparent VMAX values changed significantly more than apparent KM, the term mixed
noncompetitive inhibition was appropriate. Furthermore, when the values calculated for KIC and
KIU (binding constants of competitive and uncompetitive inhibitors, respectively) are both
calculated by SigmaPlot and are equal, the reaction is classified as pure noncompetitive (22).
Since KIC was calculated to be greater than KIU, EdAG exhibited predominantly uncompetitive
inhibition, which in this instance indicated that EdAG was binding at a non-catalytic binding site,
or ligandin site.
One explanation for the mixed noncompetitive inhibition is the suggested participation of
a separate inhibitor binding site of higher affinity for EdAG than that of the G-site or H-site. The
solvent cleft formed between the two subunits of the homodimeric GSTA1-1 could serve as the
non-catalytic binding site for EdAG, which is supported by literature (16-18,26). From these
experiments, it is not clear whether multiple binding sites and multiple substrates are
participating in the overall reaction. Another explanation of the complex mechanism of
GSTA1-1 inhibition by EdAG was irreversible binding. Michaelis-Menton plots of
noncompetitive and irreversible inhibition look similar. Noncompetitive inhibition was initially
proposed due to the Lineweaver-Burk and Hanes-Woolf plots that both suggested mixed
noncompetitive inhibition by the changing slopes and the location of the intersection of the bestfit lines in the negative x-axis. Irreversibility experiments were performed nonetheless to rule it
out and further support the mixed noncompetitive inhibition mechanism at concentrations at or
less than 1 mM EdAG.
GSTA1-1 was preincubated with various concentrations of EdAG (1000-fold
concentration range) for 30 minutes, which is ample time for covalent or irreversible binding to
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occur. At micromolar EdAG concentrations, GSTA1-1 was not irreversibly inhibited, although
minimal irreversible inhibition occurred (10-20%), which could also be attributed to less enzyme
protein recovery. At higher concentrations than expected for physiological conditions,
millimolar concentrations of EdAG (10 mM) irreversibly inactivated GSTA1-1, presumably
through covalent bond formation. EdAG concentrations of 1 mM showed more irreversible
inhibition than micromolar concentrations, but not to the same extent as the 10 mM EdAG or the
10 mM ethacrynic acid positive control, a known irreversible inhibitor of GSTs (23). The EdAG
concentration of 10 mM irreversibly inhibited GSTA1-1 to the same extent as the ethacrynic acid
control. This suggested that at lower concentrations, EdAG demonstrates reversible mixed
noncompetitive inhibition and at concentrations at or above 10 mM, EdAG demonstrates
irreversible inhibition.
EdAG is a reactive electrophile previously shown in this dissertation to be conjugated by
cysteine residues on proteins such as insulin B-chain and serum albumin. GSTA1-1 is
irreversibly inactivated by high concentrations of EdAG and is suggested to be covalently bound.
Because cysteine residues are the most nucleophilic, thus most likely, residue to conjugate
EdAG, it was hypothesized that EdAG was bound to a cysteine residue in GSTA1-1. The
GSTA1-1 homodimer contains only two cysteine residues out of a total of 444 residues, with one
on each subunit at position 112. The published crystal structure of GSTA1-1 was modeled and
showed that the two cysteine residues reside in the solvent cleft (Figure 4.3.7), where EdAG is
suggested to interact with GSTA1-1. High mass MALDI mass spectrometry was performed and
detected a mass shift in the intact GSTA1-1 when incubated with 10 mM EdAG. Incubations
with less than 10 mM did not register a mass shift for GSTA1-1 by MALDI. When digested
with trypsin, the peptide containing the cysteine residue was not detected by a Reflectron
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MALDI-TOF, thus it could not be concluded whether EdAG was covalently bound to Cys112.
An alternative hypothesis for the reversible inhibition at lower EdAG concentrations and
irreversibly at 10 mM EdAG is that EdAG is binding tightly but not covalently. Thus, at high
concentrations (nonphysiological), the noncovalent interactions are strong enough to irreversibly
inhibit GSTA1-1.
It is known that when GSH is not bound in the G-site, located in the C-terminal domain
of GSTA1-1, the native homodimer is suggested to assume numerous conformations (27-29),
although this has not been demonstrated through crystal structures. The propensity of GSH to
bind in the G-site ultimately drives GSTA1-1 to assume its normal homodimeric native
conformation that has been crystallized. When substrates are not bound, the C-terminal domain
in the apo GSTA1-1, which is mostly α-helical, can shift such that the G-site is more accessible
to GSH (30). The C-terminal can ultimately denature, however the favored binding of GSH can
slow the denaturing of the overall quaternary structure by stabilizing the C-terminal α-helix
(6,31). When a ligandin, or non-substrate, is bound in the solvent cleft, this can alter the Cterminal domain that governs access to GSH binding to the G-site (6). If EdAG is
noncovalently, but tightly binding in the solvent cleft, this could be preventing GSH from
binding the G-site, thus causing irreversible inhibition of GSTA1-1.
In conclusion, it was demonstrated in this chapter that the electrophilic dehydroalanine
analog of glutathione, EdAG, induces a concentration-dependent inhibition of GSTA1-1 activity.
At concentrations at or below 1 mM, the mechanism is reversible mixed noncompetitive, but
above 1 mM, EdAG irreversibly inactivates GSTA1-1. Since EdAG inhibits GST-mediated
busulfan metabolism and is a metabolite of the GSH adduct of busulfan, it is suggested that
product inhibition kinetics could influence busulfan pharmacokinetics. With a calculated IC50 of
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99.2 µM of EdAG for GSTA1-1, physiological concentrations of EdAG could induce GST
inhibition and prolong the presence of busulfan in the liver, potentially causing hepatotoxicity.
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Chapter 5
Reactivity of EdAG as a Radical Scavenger
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INTRODUCTION
5.1.1

Dehydroalanines as free radical scavengers

N-Acylated dehydroalanines, of which EdAG is an example, have radical scavenging
properties through a captodative mechanism (1). This unusual class of reactive oxygen species
(ROS) scavengers involves carbon-based radical intermediates that differentiate captodative
mechanisms from the scavenging properties of GSH, N-acetylcysteine, and ascorbic acid (2).
GSH is the most abundant cellular thiol and plays a major role in ROS scavenging, as well as in
transition metal transport due to the ability of the thiol moiety to donate a hydrogen atom with an
electron pair (Figure 5.1.1).

Figure 5.1.1

Glutathione redox mechanism for radicals

Amino acids and peptides that undergo a one-electron oxidation are examples of captodative
stabilization of carbon-based radicals (3). The structural features that stabilize a captodative
radical on the α-carbon of a peptide are adjacent groups consisting of a lone pair-donating amide
nitrogen and an electron-withdrawing carbonyl. Captodative free radical intermediates have
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been identified in the addition of hydroxyl radical to dehydroalanine compounds (4) as
demonstrated in Figure 5.1.2.

Figure 5.1.2

Captodative mechanism of radical scavenging by dehydroalanines

Dehydroalanine-containing compounds constitute an unusual class of radical scavengers
that have been studied for the past few decades and the proposed mechanisms are different from
redox mechanisms utilized by the more common reducing agents GSH, N-acetyl cysteine, and
ascorbic acid. N-acyldehydroalanines contain both electron-withdrawing and electron-donating
groups that form a captodative substitution system (5), which surrounds a central alpha carbon in
a dehydroalanine amino acid residue. The carbonyl system serves as the electron-withdrawing
group, allowing the β carbon adjacent to the central α carbon to obtain a partial positive charge
and make an electrophilic site for attack by ●OH. The resulting free electron is then stabilized on
the α-carbon by captodative mechanisms, where the amide group adjacent to the α carbon is the
electron-donating group and the carbonyl group adjacent to the α carbon is the electronwithdrawing group (Figure 5.1.2). The stabilized radical does not polymerize, but rather
dimerizes with other stabilized radicals (6). There are numerous examples of low molecular
weight compounds containing dehydroalanine moieties that are able to scavenge ROS such as
hydroxyl (●OH) and superoxide (O2-●) radical, as well as reducing lipid peroxidation (1,4,7-13).
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Acyldehydroalanines reduce the amount of hydroxyl radical formed in the Fenton reaction,
suggesting that these compounds could be successful as ROS scavengers in biological systems.
Suzen et al synthesized eleven N-acyl dehydroalanine compounds to study their free radical
scavenging properties by testing the protection against lipid peroxidation as well as scavenging
of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical, where the dehydroalanine compounds
protected against peroxidation but did not scavenge DPPH radical due to the lack of a redox thiol
functional group as expected (12).

In this chapter, the dehydroalanine analog of glutathione, EdAG, was tested using the
previously mentioned reactions (DPPH, Fenton reaction and EPR) to study carbon-based radical
formation through hydroxyl radical trapping. Mass spectrometry was added to structurally
identify the EdAG-hydroxyl radical adduct.
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EXPERIMENTAL PROCEDURES
5.2.1

Materials

GSH, Tris buffer, pH 7.4, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), α-(4-pyridyl Noxide)-N-tert-butylnitrone (POBN), 1,1-diphenyl-2-picrylhydrazyl (DPPH), N-acetylcysteine
(NAC), Tris buffer, pH 7.4, PBS, serum free media (SFM), Dulbecco’s modified eagle’s medium
(DMEM), fetal bovine serum (FBS), hydrogen peroxide (H2O2), sodium dichromate, xanthine,
xanthine oxidase, and ferrous sulfate (FeSO4) were purchased from Sigma-Aldrich (St. Louis,
MO). All water used was deionized with a NANOpure® water purification system (Barnstead,
San Jose, CA). RAW 264.7 mouse monocyte macrophages and BEAS-2B bronchial epithelial
cells were purchased from American Type Culture Collection (ATCC, Rockville, MD). The spin
trap DMPO was purified by charcoal decolorization and vacuum distillation to remove any
electron spin resonance (EPR)-detectable impurities.

5.2.2

Instrumentation

Ultraviolet (UV) absorbance was measured on a Beckman DU 640 UV/Vis
spectrophotometer (Beckman-Coulter, Fullerton, CA). Electron paramagnetic resonance (EPR)
(or electron spin resonance, EPR) was performed on a Bruker EMX spectrometer (Bruker
Instruments, Billerica, MA) with a flat-cell assembly. High-performance liquid chromatography
(HPLC) was performed on a Shimadzu 10 Avp binary pump HPLC system equipped with a
UV/Vis detector (Shimadzu Scientific Instruments, Columbia, MD). Mass spectrometry was
performed using an electrospray ionization (ESI) quadrupole ion trap (QIT) LCQ DECA
(ThermoFisher Scientific, Waltham, MA), capable of multi-stage mass spectrometry (MS,
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MS/MS, MS3). Accurate mass analysis was performed on an ESI LTQ-FT (ThermoFisher,
Waltham, MA).

5.2.3

Reactivity of DPPH radical with GSH and EdAG

The stable free radical DPPHy in methanol (final conc. 250 µM) was mixed with varying
concentrations of GSH, N-acetylcysteine (NAC), or EdAG (final methanol conc. was 50%)
based on literature procedures using DPPH (12). A control DPPHy solution in 1 mM Tris buffer,
pH 7.4 was used to determine baseline changes in absorbance at 515 nm over 30 minutes.
Concentrations of GSH, NAC, and EdAG ranged from 0-500 µM. Reduction of DPPHy to
reduced DPPH was calculated using the extinction coefficient for DPPHy at 515 nm, 1.16x104 M1

cm-1 (2). Experiments were performed in duplicate and averaged to determine velocity of

DPPHy to reduced DPPH.

5.2.4

Formation of the EdAG Captodative Radical In Vitro

Hydroxyl radical scavenging activity by EdAG was monitored by electron paramagnetic
resonance (EPR) experiments conducted on a Bruker EMX spectrometer (Billerica, MA).
Hydroxyl radical (●OH) was generated by the Fenton reaction containing H2O2 (0.1 mM) and
FeSO4 (0.1 mM). The reaction mixture also contained either DMPO (100 mM) or POBN (20
mM) as spin traps, and the captodative radical scavenger EdAG (0-50 mM) in a final volume of
300 µL containing PBS, pH 7.4. H2O2 was added last to initiate the formation of ●OH before the
reaction was immediately transferred to a flat-cell for EPR analysis. As the short-lived hydroxyl
radical is formed, it is immediately trapped by DMPO or POBN to obtain the DMPO-OH● or
POBN-OH● spin adduct, respectively, that is observed as a spin-trapped signal in the EPR. Note
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that only one spin trap (DMPO or POBN) is used in a run. Presence of other ●OH-scavenging
compounds will decrease that signal through competition for hydroxyl radical, and a rate
constant of scavenging for EdAG (kE) can be calculated compared to that of DMPO (kD) as
described previously (14,15). Experiments were performed under ambient air at room
temperature in triplicate, and the average values used to determine the rate of scavenging for
EdAG (kE) from the equation:
V/v -1 = kE[EdAG]/kD[DMPO], where V and v are the velocities of ●OH scavenging in the
presence and absence of EdAG, respectively, and kE and kD represent the rate constant for
hydroxyl radical scavenging by EdAG and DMPO, respectively. The literature value used for kD
was 2.1 x 10-9 M-1s-1 (16). POBN was used as a supplemental spin trap to draw further
conclusions as to the mechanism of EdAG-hydroxyl radical scavenging, and not for rates of
scavenging calculations. The mean ± SEM were plotted for each concentration of EdAG and a
two-tailed, unpaired Student’s t-test was employed to determine statistical differences.
*

Significance was determined with a p < 0.05.
The scavenging ability of EdAG was qualitatively assessed against the superoxide radical

(O2-y). Superoxide was generated by the xanthine [3.5 mM] and xanthine oxidase [2.0 U/ml]
system. A single concentration of EdAG (20 mM) was mixed with xanthine and xanthine
oxidase and immediately transferred to a flat cell for EPR analysis.

5.2.5

Mass spectrometric identification of EdAG-hydroxyl radical adduct

A Fenton reaction using 2 mM of both H2O2 and FeSO4 with either 5 or 10 mM EdAG
was performed in a test tube and immediately analyzed by LC/MS. Controls of EdAG with only
Fe2SO4 and EdAG with only H2O2 were run to ensure the desired product is strictly formed from
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the reaction of EdAG with hydroxyl radical formed by the Fenton reaction. HPLC conditions
performed on a Shimadzu 10 AVP (Shimadzu Scientific, Columbia, MD) following an injection
volume of 10 µL were as follows: A Thermo Hybercarb column (100 x 2.1 mm, 5 µm,
ThermoFisher, Waltham, MA) was used to isolate the product from other constituents in the
reaction mixture. A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v,
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol)
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9
minutes, 50→0% B; and from 9-15 minutes, 100% A. The LCQ DECA mass spectrometer was
operated in the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30
V, capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arbitrary units.
Tandem mass spectrometry (MS/MS) was performed on the major product in the reaction
mixture (m/z 581.2) with an isolation width of 1.0 amu and a percent collision energy of 30% on
the LCQ DECA ion trap mass spectrometer.

5.2.6 Accurate mass analysis of the ESG dimer

Accurate mass calculations of the EdAG-OH (the serine analog of GSH, or ESG) dimer
were performed on a LTQ-FT mass spectrometer (ThermoFisher, Waltham, MA) in the Fourier
transfer (FT) mode. The LTQ-FT calculated a theoretical mass from the chemical formula
C20H33N6O14, consistent with protonated ESG dimer. The Fenton reaction consisting of 2 mM of
both H2O2 and FeSO4 was mixed with 10 mM EdAG to produce the ESG dimer and directly
injected into the LTQ-FT mass spectrometer for accurate mass analysis. The observed accurate
mass obtained and its accuracy compared to the theoretical accurate mass was calculated. Mass
differences of 5 ppm or less from the theoretical mass are considered to be accurate. Tandem
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MS was performed in the FT mode on the LTQ-FT to obtain accurate mass calculations of the
MS/MS fragment ions of the ESG dimer. The parent ion m/z 581.20 was fragmented with a
collision-induced dissociation (CID) energy setting of 35.

5.2.7

Reaction of EdAG with Hydroxyl Radical (●OH) in RAW 264.7 Cells
°

RAW 264.7 cells (3x106/well) were cultured in DMEM over 24 hours in a 37 C
incubator. The cells were then incubated with varying concentrations of EdAG for a period of 1
°

hour in a 37 C incubator. After 1 hour, the cells were transferred to a mini centrifuge tube,
followed by the addition of potassium tetraperoxochromate (source of Cr[VI]) and DMPO to
induce ROS production (specifically yOH) and trap radicals for detection in EPR, respectively.
The solution was mixed and quickly transferred to a flat cell for EPR analysis.

5.2.8

EdAG Cell Permeability

Six wells of 500,000 BEAS-2B (bronchial epithelial cells) were plated overnight in a 37
°C incubator in DMEM growth serum. Solutions of EdAG in PBS (100, 200, and 500 µM) were
aliquoted and 2 mL added to cells after 2 mL of fetal serum albumin (FBS) growth media was
removed. EdAG was incubated with cells for 1 hour at 37 °C. Afterwards, 1 mL of media was
removed and transferred to a mini-centrifuge tube and centrifuged at 13,000 rpm for 15 minutes
at 4 °C. The supernatant, which contained EdAG that did not enter cell, was analyzed by LC/MS
to quantify EdAG. The remaining media was removed from each well and replaced with 500 µL
of either deionized water (to 3 wells containing each EdAG concentration) or 0.05% digitonin (to
other 3 wells) in order to lyse the cells. Cells were immediately scraped to detach them from the
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plate and the 500 µL media was transferred to a mini-centrifuge tube where it sat for 30 minutes
at room temperature to lyse the cell. After 30 minutes, tubes were centrifuged at 13,000 rpm for
15 minutes at 4 °C to removed cell fractions and obtain cytosol as supernatant. Samples were
then analyzed by LC/MS to quantify EdAG in cytosol of cells. Chromatographic separation was
achieved using a Thermo Hypercarb column (100 x 2.1 mm I.D., 5µm particle size)
(ThermoFisher, Waltham, MA). A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v,
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol)
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9
minutes, 50→0% B; and from 9-15 minutes, 100% A. The LCQ DECA mass spectrometer was
operated in the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30
V, capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arb. units. The
following ions were monitored: m/z 274, and m/z 308, corresponding to EdAG and GSH. GSH
was monitored to determine if cells were effectively lysed. The presence of GSH in cell lysates
after addition of digitonin confirmed the lysing of the cells.
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RESULTS
5.3.1

Comparison of the reactivity of GSH, N-Acetylcysteine and EdAG with DPPH

radical

In comparison to Suzen et al that demonstrated the inability of dehydroalanine-containing
compounds to scavenge DPPH radical (DPPH●) (12), EdAG was mixed with DPPH● to
determine its redox capabilities. Reduced GSH and N-acetylcysteine in 100 mM Tris buffer, pH
7.4, when mixed with a final concentration of 250 µM DPPH● in methanol, were effective in
reducing the absorbance of DPPH● at 515 nm. Presumably, GSH and N-acetylcysteine were
oxidized to disulfides concomitantly with the conversion of DPPH● to reduced DPPH. When
present in equimolar amounts to DPPH●, GSH and N-acetylcysteine reduced the radical at rates
of 24.1 and 29.9 nmoles/min, respectively (Figure 5.3.1). Both GSH and N-acetylcysteine
scavenged DPPH● as expected, whereas EdAG was ineffective in reducing DPPH● to reduced
DPPH. EdAG scavenged at a statistically significant slower rate (2.8 nmoles/min), suggesting
that EdAG scavenged radicals by a mechanism different from the sulfhydryl agents, GSH and Nacetylcysteine. A two-tailed, unpaired Student’s t-test was used to calculate significant
differences in reduction rates (*P<0.05 for reactions containing EdAG versus GSH control were
considered statistically significant). The results of the DPPH radical reduction experiment were
similar to the weak or absent reactivity with DPPH● by other N-acyl dehydroalanine compounds
(12).

128

Figure 5.3.1

5.3.2

Reduction of DPPH radical

Radical scavenging activity of EdAG

The reactivity of EdAG with hydroxyl radical was determined by generating ●OH with
the Fenton reaction in the presence of a spin trap (DMPO or POBN), and EdAG as monitored by
EPR. EdAG (0-50 mM) was added to the reaction mixture containing FeSO4, DMPO, and H2O2.
An obvious decrease in the spin adduct (DMPO-OH●) EPR signal was observed in an EdAG
concentration-dependent manner, suggesting that EdAG is competing with DMPO for
scavenging hydroxyl radical (Figure 5.3.2). A reaction rate constant (kE) of EdAG hydroxyl
radical scavenging, determined from the signal height ratio of the signals marked with arrows
(Figure 5.3.2 A/B), was calculated to be 8.41 x 109 M-1s-1, based on equations in the literature
(14,17). Figure 5.3.2 shows typical EPR spectra of the Fenton reaction containing 100 mM
DMPO with 0 mM EdAG (Fig. 5.3.2 A), and 100 mM DMPO with 20 mM EdAG (Fig.5.3.2 B).
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A)

B)
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C)

Figure 5.3.2

EPR Spectrum of Fenton Reaction with EdAG
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Figure 5.3.3

EdAG-dependent scavenging by EPR

Figure 5.3.3 demonstrates the concentration-dependent reduction in the DMPO-OH● signal by
EdAG. The signal heights in Figure 5.3.3 are expressed as means ± SEM with n=3 for each
group, where a two-tailed, unpaired Student’s t-test was used to calculate significant difference
(* P value <0.05 for reactions containing EdAG versus control without EdAG). EdAG was also
suggested to scavenge superoxide (O2-●) produced by the oxidation of xanthine by xanthine
oxidase. A complete disappearance of the DMPO-O2● signal occurred when 20 mM EdAG was
present (data not shown).
Typically, when a radical scavenger is introduced to the Fenton reaction containing
DMPO, a simple decrease in the DMPO-OH● EPR signal is observed. When EdAG was the
scavenger, the presence of other radical species was indicated by additional absorption bands
labeled with asterisks (Fig. 5.3.2B). In comparison, the same reaction containing GSH instead of
EdAG produced no signals other than attenuated DMPO-OH● signals (Fig. 5.3.2C). EPR
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simulations were performed using WinEPR simulation software and were based on the EPR
spectra containing EdAG to aid in the identification of the other radical species present.
Analysis of hyperfine splitting patterns and simulated EPR spectra were consistent with three
radical species, consisting of DMPO-OH● and two carbon-centered radical species. The two
carbon-centered radical species are proposed to be diastereomers of DMPO-EdAG-OH●
(compound III in Scheme 5.3.1) based on a comparison to literature spectra of the products of Nacyl dehydroalanines with hydroxyl radical (17) and EPR simulations performed. Scheme 5.3.1
depicts the proposed mechanism of EdAG reaction with hydroxyl radical (I) followed by
dimerization (II) or subsequent reaction with DMPO (III).

Scheme 5.3.1 Proposed Mechanism of Hydroxyl Radical Scavenging by EdAG
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Figure 5.3.4 depicts the mechanism of hydroxyl radical trapping by the spin trapping
agents DMPO (top) and POBN (bottom). POBN was substituted as the spin trap in an attempt to
better characterize the carbon-centered radical species. A different EPR spectrum was obtained
corresponding to POBN-OH● due to the different hyperfine splitting patterns with POBN
compared to DMPO (Fig. 5.3.5A). When EdAG was introduced to the Fenton reaction
containing POBN, an obvious decrease in the POBN-OH● signal was observed, as well as the
presence of another radical species indicated by asterisks (Fig. 5.3.5B). EPR simulations again
were performed and it was concluded that the other radical species was a carbon-centered radical
that corresponds with the diastereomeric carbon-centered radicals (III) present in the DMPOcontaining reactions, albeit with POBN substituted for DMPO.

Figure 5.3.4

Mechanism of hydroxyl radical trapping
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A)

B)
*
*
*

Figure 5.3.5

5.3.3

EPR Spectra of Fenton Reaction and POBN with EdAG

Mass spectrometric identification of EdAG-hydroxyl radical adduct

Mass spectrometry was performed to aid in the identification of the adduct of EdAG and
●

OH. A Fenton reaction mixture containing both FeSO4 and H2O2 was mixed with EdAG and

immediately analyzed by LC/MS to provide structural evidence of the hydroxyl radical
conjugated to EdAG (EdAG-OH● or ESG●; I). Tandem mass spectrometry (MS/MS) was then
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performed on the major reaction product detected in the ion trap mass spectrometer at m/z 581.
The molecular weight of the product ion at m/z 581 was consistent with a dimer of hydroxylated
EdAG (HO-EdAG-EdAG-OH, aka di-γ-glutamylserylglycine; aka ESG dimer; II) and is in
accordance with the literature that carbon-centered radicals formed via captodative mechanisms
can dimerize (6).
Assignment of the mass spectral fragmentation ions consistent with the loss of water (m/z
563), two water molecules (m/z 545), and pyroglutamic acid plus water (m/z 434) suggest that
the dehydroalanine group has reacted with hydroxyl radical forming a serine residue carboncentered radical (ESG) that dimerizes into a di-γ-glutamylserylglycine compound (Figure 5.3.6).
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Figure 5.3.6

Accurate MS/MS spectrum of ESG dimer

Scheme 5.3.1 depicts the captodative reaction proposed to occur when EdAG scavenges
hydroxyl radical forming the serine analog of glutathione radical intermediate (I) that either
dimerizes (II) or is trapped with DMPO (III). The mass spectral evidence supports a mechanism
where ESG● (I) condenses with another I to form a stable ESG dimer (II).
Accurate mass spectrometry, performed on a Fourier-transfer mass spectrometer (FTMS), calculated the theoretical accurate mass for the chemical formula of the ESG dimer (II) as
581.20493 amu. The observed accurate mass spectrum of the dimer from addition of EdAG to
the Fenton reaction was 581.20474 amu, with a difference of 0.3 ppm. FT-MS/MS was
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performed in the accurate mass spectrometer and the resulting product ions were 563.19437 amu,
545.18389 amu, and 434.15202 amu, which are consistent with the neutral losses of one water
molecule (18.0106 amu), two water molecules (36.0212 amu), and pyroglutamic acid plus water
(147.053 amu), respectively. Thus, the major product formed in the reaction of iron, hydrogen
peroxide, and EdAG was structurally identified as compound II (Scheme 5.3.1).

5.3.4

Reaction of EdAG with Hydroxyl Radical (●OH) in RAW 264.7 Cells

Due to the successful captodative scavenging of ●OH by EdAG in vitro, it was desired to
apply this in cells. RAW 264.7 cells were grown overnight in fetal bovine serum (FBS),
followed by exposure to EdAG for one hour before addition of chromium to induce ●OH
production intracellularly and DMPO to scavenge ●OH radicals and obtain a control EPR signal.
EdAG was found to be unable to scavenge hydroxyl radical intracellularly. There was no
significant decrease in the DMPO-OH● spin adduct signal in the EPR. It was hypothesized that
EdAG might be getting conjugated by GSH upon entering the cell, thus forming GSG and
eliminating its captodative ability to scavenge hydroxyl radical. A more plausible explanation
was that the hydrophilic EdAG was unable to cross the cell membrane into the cell, thus unable
to scavenge hydroxyl radicals intracellularly.

5.3.5

EdAG Cell Permeability

To determine whether EdAG was traversing the cellular plasma membrane, 6 wells of
500,000 BEAS-2B (bronchial epithelial cells) were plated overnight, then incubated with 100,
200, or 500 µM EdAG in either PBS or serum free media (SFM) for 1 hour. After 1 hour, the
media was removed and analyzed by LC/MS to determine how much EdAG remained, i.e. how
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much EdAG did not enter cells. Cells were lysed with 0.5% digitonin for 30 min, centrifuged
and then analyzed by LC/MS to determine the amount of EdAG in the cytosol. GSH was
detected in the aliquots obtained after digitonin, suggesting that the cells were sufficiently lysed
to release intracellular GSH. It was determined that no EdAG was present in the cytosol
fraction, indicating that EdAG did not traverse the plasma membrane. Figure 5.3.7 shows that
EdAG is present at each concentration level (100, 200, and 500 µM), when PBS media
supernatent was run on LC/MS prior cell lysing by digitonin (PBS-sn). After the 30 min
exposure to digitonin that lysed cells, the lysate (lys+d, Figue 5.3.6) was run and LC/MS
detected no EdAG at any concentration level. The bars corresponding to intracellular EdAG
after lysis are not visible because there was no detectable EdAG. This provides an explanation
as to why EdAG did not scavenge intracellular hydroxyl radicals as detected by EPR.

Figure 5.3.7

Cell membrane excludes EdAG
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DISCUSSION
5.4

GSH is an abundant cellular antioxidant that scavenges intracellular ROS (18). In the
depleted state of GSH during busulfan treatments, other ROS scavengers may play an increased
role. N-Acyl dehydroalanine residues have been evaluated for the ability to scavenge hydroxyl
radical (1,12) due to the reactivity of the electrophilic dehydroalanine moieties. In addition to
EdAG, there are numerous examples of low molecular weight compounds containing
dehydroalanine moieties that are able to scavenge ROS such as hydroxyl (●OH) and superoxide
(O2-●) radical, as well as reducing lipid peroxidation (1,4,7-12,17,19).
As is the case for N-acyl dehydroalanine esters, compounds operating though a
captodative mechanism would not be expected to reduce DPPH radical due to the lack of a
redox-active thiol group present in GSH. Consistent with other dehydroalanines (12), EdAG did
not scavenge DPPH●, which suggests that EdAG is not a redox-based scavenger. Thus, EPR and
mass spectrometry (MS) were used to determine the mechanism by which EdAG scavenges
radicals.
EdAG scavenged ●OH generated in the Fenton reaction as shown by attenuation of the
EPR signal from spin-trapped radicals with DMPO (Figure 5.3.2). EdAG also significantly
attenuated the DMPO-O2● signal (data not shown), suggesting that EdAG also scavenged
superoxide as has been observed for other dehydroalanine scavengers of ROS (1). The radical
intermediate formed, EdAG-OH● (γ-glutamylserylglycine; I), stabilizes the free radical on the αcarbon of the resulting serine residue, where it is too unreactive to attack the alkene of another
EdAG, and in a recombination reaction, dimerizes to form compound II. The rate of the
concentration-dependent scavenging of ●OH by EdAG (kE) was calculated as 8.41 x 109 M-1s-1.
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This rate is comparable to the scavenging rate constant of the N-acyl dehydroalanine AD-5 of 4.5
x 109 M-1s-1 (17) and of the redox active resveratrol 9.45 x 108 M-1s-1 (14). The presence of
additional radical species in Figure 5.3.2B was consistent with literature (17) and EPR
simulations were performed to better characterize those radical species. Based on the known
hyperfine splitting patterns for DMPO-OH● (aN ≅ aH ≅ 14.9 gauss), there were two additional
radical species suggested to be present with hyperfine splittings consistent with aN > aH, which
indicated carbon-centered radicals. Further analysis of the simulation results revealed that the
two carbon-centered radicals present resembled diastereomers of the same compound, suggested
to be compound III from Scheme 5.3.1.
A second spin trap, POBN, was used to further characterize the hydroxyl radical
scavenging properties of EdAG and assess the validity of diastereomers of spin traps adducted to
compound I. The use of a different spin trap aside from DMPO could help differentiate each
carbon-centered radical species by EPR. Figure 5.3.5B does show the presence of another
radical species (other than POBN-OH●) as indicated by asterisks, but EPR simulations
determined there to be only one carbon-centered radical species present, not two as the case
when DMPO was the spin trap. It was concluded that both spin traps adduct compound I at a
chiral center, however POBN produces only one carbon-centered radical species detectable by
EPR whereas DMPO produces diastereomers of the same carbon-centered radical species.
Alternatively, POBN could be producing diastereomers that have signals that are superimposed.
Mass spectrometric identification of the dimer (II) as a product in the Fenton reaction
with EdAG supports the indication that a captodative radical intermediate is likely to be formed
in the reaction of EdAG with hydroxyl radical (Scheme 5.3.1). Spin traps (DMPO, POBN) were
excluded from these experiments so to not produce spin trapped carbon-centered radicals, thus
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leaving only the EdAG-hydroxyl radical product. Confirmation of the structure was performed
by FT-MS/MS for accurate mass neutral loss, where II lost fragments of water and pyroglutamic
acid. Pyroglutamic acid is a common neutral loss for GSH-containing compounds when
analyzed by ESI-MS/MS (20,21). The simplicity of the MS/MS product ion spectrum of II (diγ-glutamylserylglycine) as shown in Figure 5.3.6 suggests a symmetrical compound.
A mechanism involving an energetically favorable captodative radical is a plausible
explanation for the Michael addition of hydroxyl radical to EdAG to form a carbon-centered
radical on the α-carbon of the dehydroalanine moiety. This captodative, or push-pull radical (5),
is stabilized by resonance associated with electron donation by the adjacent nitrogen atom, and
delocalization through the electron-withdrawing carbonyl group. This reactive radical (I) can
condense with a second radical to form an ESG dimer (II), or can be trapped with DMPO (III).
The dimerization is in accordance with previous studies involving hydroxyl radical and
dehydroalanine-containing compounds (6). It is interesting to note that the captodative
mechanism for scavenging radicals is different from the scavenging ability of sulfur-containing
compounds, most notably GSH and N-acetylcysteine, which involve thiyl radical intermediates
in a redox mechanism.
Because in vitro experiments were successful in determining the ability of EdAG to
captodatively trap hydroxyl radical, it was desired to apply this to a physiological setting to
determine if EdAG, when formed inside hepatocytes during busulfan metabolism, is able to
scavenge hydroxyl radicals intracellularly. During high-dose busulfan administration, GSH can
become depleted, leaving the cell vulnerable to ROS. EdAG could potentially play a protective
role by scavenging ROS. EdAG was not shown to decrease the hydroxyl radical signal. When
further investigated as to why this occurred, it was hypothesized that the hydrophilic EdAG was
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not capable of crossing the cell membrane. EdAG is a GSH analog and there are no cellular
GSH importers because each of the three individual amino acids (glutamate, cysteine, glycine)
are assembled intracellularly. Following this rationale, the cell permeability of EdAG was tested
on a bronchial epithelial cell line, which was chosen because of its accessibility (plated cells
were courtesy of George Medan). After a 1 hour incubation of EdAG with plated BEAS cells,
there was no intracellular EdAG detected by LC/MS. The hydrophilic nature of EdAG is
suggested to prohibit the intact molecule from freely crossing the cell membrane, and thus from
scavenging intracellular hydroxyl radical.
In conclusion, it was demonstrated in this chapter that the dehydroalanine-containing
EdAG can scavenge hydroxyl radical by a captodative mechanism that is in agreement with
literature references for other dehydroalanine-containing compounds. EdAG induced a
concentration-dependent scavenging of hydroxyl radical as monitored by EPR. The radical
product was structurally identified by mass spectrometry. Physiologically, this is relevant
because as busulfan is metabolized by GSH conjugation to form EdAG, numerous mechanisms
contribute to the depletion of intracellular glutathione. Glutathione plays an essential role as a
cellular redox buffer and its depletion could increase oxidation by ROS. The transformation of
GSH to EdAG represents the loss of thiol-related redox scavenging but the addition of a
captodative scavenging mechanism. Thus, EdAG is formed intracellularly and hypothetically is
present to scavenge intracellular hydroxyl and superoxide radicals in the cytosol. The scope of
this research did not extend to inducing ROS production in hepatocytes while metabolizing
busulfan to form EdAG.
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